

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

DANIEL ZEIGER,
Plaintiff,
v.
WELLPET LLC,
Defendant.

Case No. [3:17-cv-04056-WHO](#)

**ORDER ON MOTIONS FOR CLASS
CERTIFICATION, SUMMARY
JUDGMENT, AND TO EXCLUDE AND
STRIKE**

Re: Dkt. Nos. 152, 160, 163, 171, 173, 180,
188

INTRODUCTION

Defendant WellPet LLC (“WellPet”) makes premium-priced dog food that it holds out to be healthy, nutritious, natural, and high quality. According to plaintiff Daniel Zeiger, three WellPet dog foods actually contain small amounts of arsenic, lead, and bisphenol A (“BPA”). He alleges, on behalf of himself and several proposed classes, that WellPet misled consumers by failing to disclose the presence of these substances and by making claims on the products’ packaging that would lead reasonable consumers to believe the substances were not present. WellPet has numerous responses, including that arsenic and lead are naturally occurring and ubiquitous in the environment and that small amounts of the substances are likely present in many pet foods, that all three substances are impossible to fully remove from the food supply, and that they do not present a health risk in these small quantities.

Before me are WellPet’s motion for summary judgment on Zeiger’s individual claims, Zeiger’s motion to certify classes, and both parties’ motions to strike and exclude. WellPet’s motion for summary judgment is largely denied. Zeiger has shown genuine disputes of material fact about the safety of these levels of arsenic and lead in dog food. But he has not shown that these levels of BPA present any risk. He has also shown genuine disputes of material fact about

1 most remaining issues, including whether reasonable consumers would be misled by the
2 representations and omissions.

3 Zeiger has also met many of the requirements for certification under Federal Rule of Civil
4 Procedure 23(b)(3). He has not, however, put forward an admissible damages model or shown
5 that he can. As a result, his motion to certify under Rule 23(b)(3) is denied. Because the lack of
6 an admissible damages model is the only barrier to certification and it appears possible that such a
7 model could be advanced, Zeiger has leave to renew his motion with a new damages model. His
8 motion to certify classes under Rule 23(b)(2) is granted; the classes he proposes shall be certified
9 for purposes of injunctive relief.

10 BACKGROUND

11 I. THE WELLNESS PRODUCTS

12 This case concerns three dog food products manufactured and marketed by WellPet as part
13 of its “Wellness” line: Complete Health Adult Whitefish & Sweet Potato (the “Sweet Potato
14 Product”), Complete Health Grain Free Adult Whitefish & Menhaden Fish Meal (the “Menhaden
15 Product”), and CORE Ocean (with Whitefish, Herring Meal and Salmon Meal) (the “CORE
16 Ocean Product”) (collectively, the “Wellness Products”). Zeiger’s broad theory is one of
17 misrepresentation. He alleges that WellPet marketed the Wellness Products as “premium dog
18 food” at a “premium price” that held itself out as “natural and nutritious.” *See, e.g.*, Plaintiff’s
19 Motion for Class Certification (“Cert. Mot.”) [Dkt. No. 163] 2–3. In reality, Zeiger claims, the
20 Wellness products contain lead, arsenic, and BPA, the presence of which WellPet did not disclose
21 to consumers. *Id.*

22 The Wellness Products are sold in bags ranging from 4 lb. to 30 lb. Declaration of Laura
23 Marseglia [Dkt. No. 162-3] ¶ 4. Their packaging includes, among other things, the ingredients
24 included in the dog food and percentages of nutrients. Declaration of Gregory G. Kean (“Kean
25 Decl.”) [Dkt. No. 162-2] ¶ 15. They also contain, Zeiger alleges, a group of misleading
26 “marketing claims.” Those statements are: (1) “Uncompromising Nutrition,” (2) “Unrivaled
27 Quality Standards,” (3) “Natural,” (4) “Nothing in excess and everything in balance,” and (5)
28 “Complete health” (collectively, the “Wellness Statements”). *See* Second Amended Complaint

1 (“SAC”) [Dkt. No. 95] ¶¶ 10, 11, 16, 46. Because the Wellness Statements are a focus of the
2 parties’ class certification dispute, they are discussed further below. As a general matter, the
3 statements on the Wellness Products’ packaging have changed over time in content, location, and
4 size. Kean Decl. ¶ 16. They also change from product to product. *Id.*

5 Both parties agree that the Wellness Products are geared toward nutrition-conscious
6 consumers. The record also shows that pet foods that are viewed as high in nutritional value, use
7 high-quality ingredients, and use only “natural” ingredients can be sold at higher prices than other
8 pet foods. *See, e.g.*, Cert. Mot. 2 (collecting statements by WellPet to that effect). Zeiger argues
9 that WellPet has designed its brand and the Wellness Products’ brands around an image that
10 conforms to these ideals. According to Zeiger, everything from the name “WellPet” to the brand
11 name “Wellness” to the Wellness Statements are intended to evoke this natural, healthy, high-
12 quality image. Of particular importance to this suit, Zeiger argues that the brand is designed to
13 convey that there are no “chemicals or contaminants” in the Wellness Products.

14 **II. ARSENIC, LEAD, AND BPA**

15 Zeiger contends that the Wellness Products either contained or had a risk of containing
16 “detectable amounts” of arsenic, lead, and BPA. Cert. Mot. 3; SAC ¶¶ 2, 12, 13, 21, 45.

17 Arsenic and lead are heavy metals. *See, e.g.*, Report of Dr. Gary Pusillo (“Pusillo Rep.”)
18 [Dkt. No. 163-2] at 16–17.¹ There is no evidence that WellPet intentionally adds arsenic or lead to
19 its products, and Zeiger does not contend otherwise. Prior to “approximately 2015,” WellPet
20 tested at least some of its products for heavy metals. *See, e.g.*, Dkt. No. 151-11, Ex. 7 at 57.
21 Zeiger and his expert contend that this testing was ineffective because (1) only a small number of
22 ingredients were tested and (2) WellPet used a detection limit of 10 or 5 parts per million (“ppm”)
23 when it could have used lower limits measured in parts per billion (“ppb”). *See* Pusillo Rep. at
24 21–22. WellPet points out that arsenic and lead can occur naturally in fish-based ingredients, so it
25 conducted 35 tests of those ingredients over two years. Kean Decl. ¶ 36–37. It represents that all
26 of those tests “yielded non-detectable levels of arsenic and lead.” *Id.* ¶ 37.

27
28

¹ Citations to exhibits attached to the parties’ briefs are to the ECF-generated page number.

1 There is also evidence that WellPet created guidelines for its suppliers that, among other
2 things, barred products with arsenic and lead and required accrediting testing for those substances.
3 *See* Dkt. No. 151-8 (supplier manual). But, according to Zeiger, these standards were never
4 enforced or communicated to raw material vendors. *See, e.g.*, Dkt. No. 151-11 at 5:11–21 (“This
5 would have been sent to our co-manufacturing suppliers—companies that make finished products
6 for us . . . I have never sent it to a raw material vendor.”). WellPet says that the guidelines were
7 only ever a draft that was later superseded. Kean Decl. ¶ 24. WellPet allegedly later removed any
8 requirement for lab tests to show an absence of heavy metals. Dkt. No. 151-8, Ex. 6 (Certificate
9 of Analysis for WellPet ingredients does not include testing for arsenic or lead).

10 BPA is a synthetic chemical found in some plastics, among other places. *See, e.g.*, Pusillo
11 Rep. at 16. Zeiger contends that WellPet’s internal quality control standards prohibit BPA in its
12 products because they seek to prevent contamination by “foreign bodies,” defined as “[a]ny
13 material which is not natural to the raw material, ingredient, packaging material, or finished
14 product[.]” *See* Dkt. No. 151-8, Ex. 5 WellPet admits that it did not and does not test for BPA.
15 *Id.*, Ex. 7. There also appears to be no requirement that WellPet suppliers test for BPA. *Id.*, Ex. 6
16 (Certificate of Analysis for WellPet ingredients requires that “this ingredient is preserved with a
17 natural antioxidant” but does not include testing for BPA).

18 Zeiger claims that BPA can be introduced into the Wellness Products through its
19 manufacturing and storage processes. Specifically, Wellness Products are placed into plastic
20 buckets at high temperatures, which creates a risk that BPA from the plastic will contaminate the
21 products. *See* Dkt. No. 151-11 at 59:12–16. Ingredients are also at one point placed into large
22 plastic bags, which Zeiger argues may lead to contamination. *Id.* at 3:24–4:11. According to a
23 laboratory analysis by one of Zeiger’s experts, “quantifiable levels of BPA” were found in 59 of
24 the 105 tested WellPet products. *See* Report of Sean P. Callan (“Callan Rep.”) [Dkt. No. 163-8] ¶
25 3.

26 The parties dispute the risk from arsenic, lead, and BPA in the Wellness Products. There is
27 evidence on this record that many pet foods contain some small amount of arsenic and lead. *See,*
28 *e.g.*, Poppenga Rep. at 10. The Food and Drug Administration (“FDA”) has remarked (albeit in

1 explanatory posts online, not in any regulatory or adjudicatory proceeding) that “[a]s a naturally
2 occurring element, it is not possible to remove arsenic entirely from the environment or food
3 supply” and “[i]t is not possible to remove or completely prevent lead from entering the food
4 supply.” *See* FDA, *Arsenic in Food and Dietary Supplements* (August 5, 2020),
5 <https://www.fda.gov/food/metals-and-your-food/arsenic-food-and-dietary-supplements>; FDA,
6 *Lead in Food, Foodwares, and Dietary Supplements* (February 27, 2020),
7 <https://www.fda.gov/food/metals-and-your-food/lead-food-foodwares-and-dietary-supplements>.
8 But even in these posts, which WellPet relies on, the FDA goes on to say that, because of these
9 facts, the FDA “seeks to limit consumer exposure to arsenic to the greatest extent feasible” and
10 “seeks to limit consumer exposure to lead in foods to the greatest extent feasible.”

11 **III. ZEIGER’S EXPERIENCES**

12 Zeiger purchased at least a \$15 bag of Wellness Product every one to three months from
13 “approximately October 2014 until July 2017.” SAC ¶ 25; Dkt. No. 152-8 at 4:1–5. (He also
14 made purchases of it before the class period. *See, e.g.*, Dkt. No. 162-16 at 14:3–11.) At that point,
15 he learned that the Wellness Products contained arsenic, lead, and/or BPA and he stopped
16 purchasing them. SAC ¶ 25. He claims that he relied on the Wellness Statements and, as a result,
17 reasonably believed the Wellness Products did not contain arsenic, lead, or BPA. *Id.* He also
18 alleges that he would not have purchased the products if he had known about the presence of these
19 substances. *Id.* WellPet interprets Zeiger to have testified that he could not recall most specifics
20 about the products he purchased; that he understands arsenic and lead are naturally occurring; that
21 he understands BPA exists in many places; and that he personally would rely on the FDA to
22 determine reasonable levels of arsenic, lead, and BPA in food.

23 **IV. PROCEDURAL HISTORY**

24 Zeiger filed this suit in September 2017 on behalf of himself and a proposed class.² Dkt.
25 Nos. 1, 33. In January 2018, I granted in part and denied in part a motion to dismiss. Dkt. No. 59.
26 Discovery began, discovery disputes ensued, and the time for discovery was repeatedly extended
27

28 ² There were previously other named plaintiffs but they have since been dismissed.

1 at the parties' requests. *See* Dkt. Nos. 72, 87, 104, 111, 119, 126, 140. In June 2018, I granted a
2 motion to amend the complaint in line with my order on the motion to dismiss. Dkt. No. 94. In
3 December 2019, Zeiger moved to file a third amended complaint, which I denied for failure to
4 show diligence and for the prejudice to WellPet. Dkt. No. 135.

5 The operative complaint alleges six causes of action: (1) negligent misrepresentation, (2)
6 violation of the California Consumers Legal Remedies Act ("CLRA"), (3) violation of
7 California's False Advertising Law ("FAL"), (4) violation of California's Unfair Competition Law
8 ("UCL"), (5) breach of express warranty under California law, and (6) breach of implied warranty
9 under California law.

10 On June 29, 2020, Zeiger moved for class certification on all claims. Dkt. No. 152. On
11 September 30, 2020, WellPet filed a *Daubert* motion about Zeiger's class certification experts.
12 Dkt. No. 163. On October 14, 2020, Zeiger moved to strike portions of a declaration filed by
13 WellPet. Dkt. No. 171. And on October 30, 2020, WellPet moved for summary judgment on
14 Zeiger's individual claims. Dkt. No. 180. Because the class certification motion turned in large
15 part on the summary judgment and *Daubert* motions, I granted WellPet's motion to consolidate
16 the hearing on all pending motions, Dkt. No. 186, which was held on January 27, 2021.

17 LEGAL STANDARD

18 I. EXPERT TESTIMONY

19 Federal Rule of Evidence 702 allows a qualified expert to testify "in the form of an opinion
20 or otherwise" where: (a) the expert's scientific, technical, or other specialized knowledge will help
21 the trier of fact to understand the evidence or to determine a fact in issue; (b) the testimony is
22 based on sufficient facts or data; (c) the testimony is the product of reliable principles and
23 methods; and (d) the expert has reliably applied the principles and methods to the facts of the case.
24 Fed. R. Evid. 702. Expert testimony is admissible under Rule 702 if it is both relevant and
25 reliable. *See Daubert v. Merrell Dow Pharm., Inc.*, 509 U.S. 579, 589 (1993). "[R]elevance
26 means that the evidence will assist the trier of fact to understand or determine a fact in issue."
27 *Cooper v. Brown*, 510 F.3d 870, 942 (9th Cir. 2007); *see also Primiano v. Cook*, 598 F.3d 558,
28 564 (9th Cir. 2010) ("The requirement that the opinion testimony assist the trier of fact goes

1 primarily to relevance.”) (internal quotation marks omitted).

2 Under the reliability requirement, the expert testimony must “ha[ve] a reliable basis in the
3 knowledge and experience of the relevant discipline.” *Primiano*, 598 F.3d at 565. To ensure
4 reliability, the court must “assess the [expert’s] reasoning or methodology, using as appropriate
5 such criteria as testability, publication in peer reviewed literature, and general acceptance.” *Id.*
6 These factors are “helpful, not definitive,” and a court has discretion to decide how to test
7 reliability “based on the particular circumstances of the particular case.” *Id.* (internal quotation
8 marks and footnotes omitted). “When evaluating specialized or technical expert opinion
9 testimony, the relevant reliability concerns may focus upon personal knowledge or experience.”
10 *United States v. Sandoval-Mendoza*, 472 F.3d 645, 655 (9th Cir. 2006).

11 The inquiry into the admissibility of expert testimony is “a flexible one” in which “[s]haky
12 but admissible evidence is to be attacked by cross examination, contrary evidence, and attention to
13 the burden of proof, not exclusion.” *Primiano*, 598 F.3d at 564. The burden is on the proponent
14 of the expert testimony to show, by a preponderance of the evidence, that the admissibility
15 requirements are satisfied. *Lust By & Through Lust v. Merrell Dow Pharm., Inc.*, 89 F.3d 594,
16 598 (9th Cir. 1996); *see also* Fed. R. Evid. 702 advisory committee’s note.

17 **II. SUMMARY JUDGMENT**

18 Summary judgment on a claim or defense is appropriate “if the movant shows that there is
19 no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of
20 law.” Fed. R. Civ. P. 56(a). In order to prevail, a party moving for summary judgment must show
21 the absence of a genuine issue of material fact with respect to an essential element of the non-
22 moving party’s claim, or to a defense on which the non-moving party will bear the burden of
23 persuasion at trial. *See Celotex Corp. v. Catrett*, 477 U.S. 317, 323 (1986). Once the movant has
24 made this showing, the burden then shifts to the party opposing summary judgment to identify
25 “specific facts showing there is a genuine issue for trial.” *Id.* The party opposing summary
26 judgment must then present affirmative evidence from which a jury could return a verdict in that
27 party’s favor. *Anderson v. Liberty Lobby*, 477 U.S. 242, 257 (1986).

28 On summary judgment, the court draws all reasonable factual inferences in favor of the

1 non-movant. *Id.* at 255. In deciding a motion for summary judgment, “[c]redibility
2 determinations, the weighing of the evidence, and the drawing of legitimate inferences from the
3 facts are jury functions, not those of a judge.” *Id.* However, conclusory and speculative testimony
4 does not raise genuine issues of fact and is insufficient to defeat summary judgment. *See*
5 *Thornhill Publ’g Co., Inc. v. GTE Corp.*, 594 F.2d 730, 738 (9th Cir. 1979).

6 **III. CLASS CERTIFICATION**

7 “Before certifying a class, the trial court must conduct a rigorous analysis to determine
8 whether the party seeking certification has met the prerequisites of Rule 23.” *Mazza v. Am. Honda*
9 *Motor Co., Inc.*, 666 F.3d 581, 588 (9th Cir. 2012) (internal quotation marks omitted). The party
10 seeking certification has the burden to show, by a preponderance of the evidence, that certain
11 prerequisites have been met. *See Wal-Mart Stores, Inc. v. Dukes*, 564 U.S. 338, 348–50 (2011);
12 *Conn. Ret. Plans & Trust Funds v. Amgen Inc.*, 660 F.3d 1170, 1175 (9th Cir. 2011).

13 Certification under Rule 23 is a two-step process. The party seeking certification must first
14 satisfy the four threshold requirements of Rule 23(a). Specifically, Rule 23(a) requires a showing
15 that: (1) the class is so numerous that joinder of all members is impracticable; (2) there are
16 questions of law or fact common to the class; (3) the claims or defenses of the representative
17 parties are typical of the claims or defenses of the class; and (4) the representative parties will
18 fairly and adequately protect the interests of the class. Fed. R. Civ. P. 23(a).

19 Next, the party seeking certification must establish that one of the three grounds for
20 certification applies. *See* Fed. R. Civ. P. 23(b). Zeiger seeks certification under Rule 23(b)(3),
21 which requires him to establish that “the questions of law or fact common to class members
22 predominate over any questions affecting only individual members, and that a class action is
23 superior to other available methods for fairly and efficiently adjudicating the controversy.” Fed.
24 R. Civ. P. 23(b)(3). He also seeks certification under Rule 23(b)(2) for an injunctive relief class.
25 And, in the alternative to the (b)(3) class, he seeks certification under Rule 12(c)(4) for any issues
26 that I determine are fit for class treatment.

27 In the process of class-certification analysis, there “may entail some overlap with the
28 merits of the plaintiff’s underlying claim.” *Amgen Inc. v. Connecticut Ret. Plans & Trust Funds*,

1 568 U.S. 455, 465–66 (2013) (internal quotation marks omitted). However, “Rule 23 grants courts
2 no license to engage in free-ranging merits inquiries at the certification stage.” *Id.* at 466. “Merits
3 questions may be considered to the extent—but only to the extent—that they are relevant to
4 determining whether the Rule 23 prerequisites for class certification are satisfied.” *Id.*

5 **DISCUSSION**

6 **I. MOTIONS TO STRIKE AND EXCLUDE**

7 **A. WellPet’s *Daubert* Motion**

8 WellPet moves to exclude the opinions of two of Zeiger’s technical experts and of his
9 damages experts.

10 **i. Dr. Pusillo**

11 WellPet moves to exclude several opinions of Dr. Gary Pusillo, who opines, among other
12 things, that (1) there is no safe amount of arsenic, lead, or BPA in dog food for consumption by
13 dogs and (2) WellPet could have but did not prevent inclusion of arsenic, lead, and BPA in its dog
14 food. *See* WellPet’s Motion to Exclude Certain of Plaintiff’s Expert Testimony (“WellPet Strike
15 Mot.”) [Dkt. No. 163].

16 WellPet first attacks Pusillo’s qualifications to opine on these subjects at all. It argues that
17 Pusillo is an animal nutritionist, but that the above opinions he renders are about toxicology and
18 pet food manufacturing respectively. *See* WellPet Strike Mot. 3, 10–11. Zeiger agrees that Pusillo
19 is a nutritionist, but argues that he is nonetheless qualified to render his opinions due to his general
20 experience in animal food safety and testing. *See* Opposition to the WellPet Strike Mot. (“WellPet
21 Strike Oppo.”) [Dkt. No. 174] 5–8. WellPet then challenges the reliability of each opinion.

22 Pusillo’s master’s degree is in “animal production” and his Ph.D. is in “animal nutrition.”
23 Pusillo Rep. at 7. He is currently the president and owner of a company that, by Pusillo’s
24 description, “develop[s] and formulate[s] specialty animal feeds, supplements, and health care
25 products for domestic and exotic animals[;] . . . provides nutritional consulting advice to animal
26 owners, and manufacturers involved in the animal industry[; and] . . . provides investigative
27 forensic and expert witness services for claims and litigated cases involving animal deaths,
28 production abnormalities, and injuries.” *Id.* He also works and has previously worked at several

1 other companies in nutrition-related roles. *See id.* He has testified or been deposed in five cases.
2 *Id.* at 13.

3 1. Opinion that there is no safe level of arsenic, lead, and BPA

4 WellPet’s first argument is that it is for a toxicologist, not a nutritionist, to opine on what
5 levels of certain chemicals are safe in pet food. WellPet Strike Mot. 3–4. Here, the evidence is
6 that Pusillo has long experience (in addition to a Ph.D.) in animal nutrition, which includes
7 understanding the effects of substances in animal food on those animals’ health. His CV shows
8 that he has published papers analyzing the effects of substances in food on animals. *See* Pusillo
9 Rep. at 9–12. In his deposition in a previous case that both parties rely on, Pusillo testified that he
10 has, within the scope of his work, analyzed lab testing results, including for heavy metals. *See*
11 Dkt. No. 174-2 at 114:21–24. While the opinions might or might not be most appropriate for a
12 toxicologist or chemist, *Daubert* does not require that the expert with the best possible
13 qualifications testify, it requires that the expert be sufficiently qualified and his or her testimony be
14 reliable. As an experienced animal nutritionist, Pusillo is qualified to opine about the effects of
15 substances that animals ingest on their health.

16 WellPet relies on *Lucido v. Nestle Purina Petcare Co.*, 217 F. Supp. 3d 1098 (N.D. Cal.
17 2016). *See* WellPet’s Reply in Support of the WellPet Strike Mot. (“WellPet Strike Reply”) [Dkt.
18 No. 179] 2. WellPet argues that, in that case, a veterinarian with a specialty in toxicology offered
19 opinions on the adequacy of a company’s testing procedures but the court excluded them as
20 unreliable because they “were not within ‘his specialized knowledge as a veterinarian.’” *Id.*
21 (quoting *Lucido*, 217 F. Supp. at 1107). As an initial matter, *Lucido* went on to hold that the
22 veterinarian *was* qualified to testify about the potential *health risks* of the dog food. 217 F. Supp.
23 3d at 1107. While he may not have been “calling upon his specialized knowledge as a veterinarian
24 to express his opinions about the adequacy of Purina’s *testing procedures*,” *id.* (emphasis added),
25 he did have “knowledge about [the toxins at issue],” *id.* at 1108. (The court then excluded those
26 opinions on reliability grounds.) More to the point, Pusillo is an animal nutritionist, not a
27 veterinarian, and is opining about animal nutrition and its effects on animal health.

28 WellPet next contends that this opinion is not reliable under *Daubert*. WellPet Strike Mot.

1 4–10. I separate out the opinion into lead and arsenic on the one hand and BPA on the other.

2 Pusillo bases his opinion that there is no safe level of lead and arsenic in the dog food on
3 the established fact of “bioaccumulation.” Pusillo Rep. at 15–18. Bioaccumulation is essentially
4 the build-up of a substance as it is ingested over time. *Id.* at 17–18. WellPet does not dispute that,
5 as a general matter, bioaccumulation of substances is recognized to occur. *See* WellPet Strike
6 Reply 2–3. And both parties’ experts agree that lead and arsenic *in certain concentrations* are
7 dangerous. *See* Report of Dr. Robert Poppenga (“Poppenga Rep.”) [Dkt. No. 162-13] at 5
8 (discussing arsenic and lead poisoning).

9 Pusillo cites several published studies to support various aspects of his opinion. He
10 characterizes a 2013 study as finding that “non-absorbed heavy metals have a direct impact on the
11 gut microbiota. In turn, this may impact the alimentary tract and overall gut homeostasis.” Pusillo
12 Rep. at 16 (citing Breton, J., at al. *Ecotoxicology inside the gut: impact of heavy metals on the*
13 *mouse microbiome*, 14 BMC Pharmacology and Toxicology 62 (2013)). Though that study
14 concerned rodents, Pusillo opines that the principle applies to dogs too. *Id.* Additionally, he cites
15 evidence that “trace amounts” of arsenic ingested by humans can, over extended periods, have
16 deleterious health consequences. *Id.*

17 WellPet musters a number of counterarguments, but all go to weight, not admissibility.
18 The role of a court at the *Daubert* stage is reliability gatekeeper, not factfinder. WellPet first
19 attacks the studies Pusillo relies on as being inconclusive. WellPet Strike Reply 2–4. Pusillo has
20 cited no studies in which bioaccumulation of heavy metals was conclusively shown to be a health
21 risk in dogs. And WellPet is right that none of the studies establish all aspects of his opinions,
22 which is why his report is necessary to connect them. The 2013 study, for instance, concerned
23 lead and cadmium, not arsenic. *Id.* But Pusillo opines that it is a feature of *heavy metals* that they
24 bioaccumulate, as his other evidence arguably shows. Similarly, WellPet attacks the study as only
25 finding possible impacts on health, as opposed to certain ones; and it cites that paper’s call for
26 further study. WellPet Strike Mot. 4–5. The strength of the evidence of health effects and need
27 for more study go to weight because Pusillo has illustrated how his theory works.

28 WellPet also faults Pusillo for his purported “failure to consider the dose and duration of

1 possible exposure . . . instead reaching the conclusion that there is no safe level without first doing
2 any analysis of dose or duration.” WellPet Strike Mot. 5–6; WellPet Strike Reply 3–4. That
3 misunderstands Pusillo’s opinion. The issue is not that any single dose is harmful, it is that
4 ingesting these substances would not be safe for dogs because they bioaccumulate to unsafe levels.

5 With respect to lead in particular, WellPet contends that Pusillo’s opinion runs afoul of the
6 Supreme Court’s instruction that there cannot be “too great an analytical gap between the data and
7 the opinion proffered.” *Gen. Elec. Co. v. Joiner*, 522 U.S. 136, 146 (1997). The leap it identifies
8 is to the conclusion “that *any* measurable amount of lead in pet food—even less than 1 ppm—is
9 unsafe for dogs.” WellPet Strike Mot. 9. No such leap was made. Pusillo’s opinion is that lead,
10 which is established to be dangerous at sufficiently high concentrations, bioaccumulates.
11 Therefore, even small doses add up to a health hazard over time. WellPet’s arguments are, again,
12 for the jury.

13 WellPet points to guidance from the FDA and European Union regulatory guidelines that
14 purport to address safe levels of lead and arsenic in pet food. *Id.* 6–7. As an initial matter, many
15 of the documents that WellPet relies on are in the nature of guidance memoranda, not the
16 agencies’ authoritative positions. One of WellPet’s primary exhibits, for instance, explicitly states
17 it is “draft guidance” that is “for comment purposes only” and is “not for implementation.” Dkt.
18 No. 162-12. Additionally, much of the evidence WellPet relies on shows, at most, that the
19 substances have not been named hazards, not that they have been declared safe at the levels the
20 Wellness Products are alleged to have. *See id.* at 139–155 (table of hazards WellPet relies on that
21 does not include the substances). In any event, this dispute is here on a *Daubert* motion. So long
22 as *Pusillo*’s methodology is sound and his opinions reliable, it does not matter what countervailing
23 evidence there is, even if it is strong. The only way countervailing evidence would negate
24 Pusillo’s opinion is if it showed it was unreliable, not just that it was disputed.

25 WellPet points again to *Lucido*. There, however, there was no bioaccumulation theory
26 presented and the expert’s opinion was excluded as being unsupported. *See Lucido*, 217 F. Supp.
27 3d at 1107. Pusillo’s opinion on the safety of lead and arsenic is admissible.

28 I agree with WellPet, however, that Pusillo’s opinion that no amount of BPA is safe is

1 unsupported and has not been shown to be reliable. Pusillo’s theory on BPA is not that it
2 bioaccumulates. Instead, Zeiger identifies two sources for Pusillo’s conclusion that *no* amount of
3 BPA is safe in dog food: Pusillo’s experience and background and a 2016 study. *See* WellPet
4 Strike Oppo. 12–13.

5 The 2016 study is not sufficient support for Pusillo’s broad assertion about BPA. In that
6 study, 14 dogs were fed a BPA-laced diet or a control diet over 14 days. *See* Zoe L. Koestel, et al,
7 *Bisphenol A (BPA) in the serum of pet dogs following short-term consumption of canned dog food*
8 *and potential health consequences of exposure to BPA*, 579 *Science of The Total Environment*
9 1804 (2017). While BPA concentrations were greater for dogs on the BPA diet, “there was no
10 difference in circulating concentrations of BPA between dogs on either of these two diets.” *Id.* at
11 1808. That study did not reach any causal connections and recognized the changes may have
12 resulted from changes in diet and Pusillo does not suggest that bioaccumulation occurs with
13 respect to BPA. That does not support the idea that *trace* amounts of BPA will have deleterious
14 health consequences, especially because of the lack of a bioaccumulation opinion. Indeed, the
15 study explained that “[i]t remains to be determined whether these diet-induced bacterial changes
16 result in significant health consequences.” *Id.* at 1813. It is far from a conclusion that BPA *at any*
17 *level* is a health risk. Given the weak materiality of that study, Pusillo’s nebulous assertions of
18 “experience” are insufficient to show reliability of a theory that appears to have no other scholarly
19 support. Accordingly, this opinion will be excluded.

20 2. Opinion that WellPet could have prevented inclusion of arsenic, lead,
21 and BPA

22 WellPet also moves to exclude Pusillo’s opinion that it could have prevented inclusion of
23 arsenic and lead. WellPet again attacks Pusillo’s qualifications to opine on this topic at all.
24 WellPet Strike Mot. 10. As discussed, Pusillo has a long history in animal nutrition, including in
25 formulating diets and laboratory testing. He is qualified to offer opinions about WellPet’s food
26 formulation and testing procedures. The core of his opinion on this topic is that WellPet could
27 have identified the substances through testing its ingredients and then excluded those that tested
28 positive. *See* Pusillo Rep. 21–24. That opinion is in his wheelhouse as someone who analyzes how

1 best to provide nutrients in food to animals. WellPet responds that someone would need expertise
2 in animal food manufacturing to render these opinions. WellPet Strike Reply 4. Again, however,
3 Pusillo does not need to be the most specialized possible expert to opine on a subject, he must
4 have expertise from his experience, as he does.

5 However, I find that Pusillo is not qualified to opine about how WellPet could reduce the
6 risk of BPA (as opposed to lead and arsenic). To form *that* opinion, Pusillo relies on the assertion
7 that BPA contamination can occur with exposure to plastic at high heat that can happen during the
8 storage process of the food. Pusillo Rep. at 24. Pusillo is a nutritionist, not a food safety expert, a
9 chemist, or a toxicologist. Lead and arsenic exist in food and he is qualified to opine about their
10 nutritional effects. But BPA is a synthetic compound that, Zeiger alleges, enters due to how the
11 Wellness Products are moved and stored. It is beyond the ken of a nutritionist to describe the
12 mechanisms for that synthetic chemical infiltrating the products.

13 WellPet also argues that the opinions are unreliable. It argues that Pusillo does not opine
14 that it is a common practice to perform this testing and quality control in the *pet food* industry
15 (presumably as opposed to human food) or for the ingredients to which the practice would apply.
16 WellPet Strike Mot. 11. That objection goes to the weight of his opinion and would not alter his
17 central opinion about the possibility avoiding these substances through testing. Additionally,
18 WellPet points to science that it argues is contrary to Pusillo’s conclusion; the materials it relies on
19 have largely been discussed already because they relate to the safety and ubiquity of these
20 substances. *Id.* 11–12. Again, the existence of contrary evidence is not itself sufficient to exclude
21 an otherwise reliable opinion under *Daubert*.

22 Relatedly, WellPet argues that because the levels of arsenic and lead are so low, there is no
23 need to exclude them. *Id.* That is the very merits issue to be determined, not a reason to exclude
24 Pusillo’s opinion that removal is *possible*.

25 WellPet challenges Pusillo’s discrete opinion that “WellPet products contained arsenic and
26 lead for years.” WellPet Strike Mot. 13. That opinion is not based on any substantive analysis in
27 his report and Zeiger makes no attempt to defend it in his Opposition. It will be excluded.

28 In sum, Pusillo’s opinion on lead and arsenic is admissible (except for his opinion that the

1 products contained lead and arsenic “for years”); his opinion on BPA will be excluded.

2 **ii. Dr. Callan**

3 WellPet moves to exclude several opinions of Dr. Sean Callan, another of Zeiger’s experts
4 who analyzed WellPet’s products in a laboratory for traces of BPA. *See* WellPet Strike Mot. 13–
5 14. To form his opinions, Callan tested 105 of WellPet’s products for BPA and found that 59
6 contain “quantifiable levels of BPA.” *Id.* Ex. G (“Callan Rep.”) [Dkt. No. 163-8] at 2. Callan
7 offers several opinions about these results that WellPet does not challenge.

8 WellPet objects, though, to Callan’s opinions about WellPet’s quality control procedures
9 and possible sources of BPA in pet food. *Id.* at 5–6. The portion of the report that contains these
10 opinions reads in its entirety:

11 Upon review of the disclosure on the Wellpet website around their purported transition to
12 BPA-free packaging, I find no mention of the methodology used to screen for BPA. As
13 such, I am unable to review the suitability of their methodology in this regard. However, it
14 should be noted that BPA in pet food is not confined to packaging, and may result from
15 many other components of the supply chain processing, raw ingredient packaging, etc.
16 Furthermore, the variability in the levels of BPA observed in the 105 products tested,
17 coupled with the proportion of products with quantifiable levels of BPA suggests a
18 systemic quality control issue beyond wet food packaging.

19 *Id.*

20 WellPet argues that Callan is not qualified to render these opinions and that he fails to
21 employ reliable principles or methods to reach them. I agree that Callan has no expertise that
22 would permit him to opine on this to the jury and that he has not offered any reliable foundation
23 for these opinions.

24 Callan’s master’s degree and Ph.D. are in psychology and his post-doctoral training is in
25 molecular neuroscience and molecular biochemistry. *Id.* Currently, he is a senior vice president at
26 Ellipse Analytics, a lab that is accredited to test for BPA. *Id.* at 2, 4. He represents that he
27 “specialize[s] in data analytics, statistics, toxicology and neuropharmacology” and has “taught
28 statistics and research design courses.” *Id.* at 2–3. He has served for four years in various roles at
29 Ellipse, including in research and as a lab technician. *Id.* at 13.

30 Zeiger argues that Callan is qualified to render the above opinions about WellPet’s quality
31 control and the other possible sources of BPA aside from packaging because he “is a laboratory

1 technician” and is “qualified to review and attest to the suitability of testing methodologies to
2 properly test and screen for BPA.” WellPet Strike Oppo. 15. While that experience renders him
3 an expert in the laboratory testing he performed and analyzed, that is not the focus of WellPet’s
4 motion. Zeiger has not shown that Callan is qualified to testify about possible sources of BPA in
5 WellPet’s food. He is a psychologist, and any other relevant experience that he has comes from
6 his role analyzing lab results. Expert testimony about potential *other* sources of BPA comes
7 neither from psychology nor from the results.

8 Zeiger also relies on one talk Callan gave to the Association of Official Analytical
9 Collaboration that it characterizes as being about “ensuring reliability and reproducibility of
10 analytical chemistry analyses of, among other things, pet food.” *Id.* This single talk—the
11 description of which is quite vague—does not reveal any level of expertise in the areas that would
12 permit Callan to form the opinions above. It simply points back to him being qualified to perform
13 the analysis of the composition of pet food, but not more.

14 This opinion will also be excluded on reliability grounds because Callan never indicates
15 what it is based on. The methodology in Callan’s report is entirely related to how his laboratory
16 analysis of the products was performed. *See* Callan Rep. at 3. The results of that lab work are not
17 challenged and appear admissible. Yet the opinion quoted above—which is Callan’s entire
18 opinion on this topic—is couched as an “interpretation” of these results. *Id.* at 5. He never
19 explains how he knows that “BPA in pet food is not confined to packaging,” how it “may result
20 from many other components of the supply chain,” or how “variability” in the levels of BPA and
21 “proportion” with BPA “suggest[] a systemic quality control issue” aside from packaging. *Id.* at
22 5–6. Zeiger argues that the opinion “is based on his experience in evaluating and assessing test
23 results,” WellPet Strike Oppo. 15, but it goes beyond analyzing the lab results to analyzing the
24 sources of and mechanisms that lead to BPA contamination. These opinions may be true, but
25 there is no way to test their reliability and Callan is not qualified to opine as an expert on them.

26 The motion to strike Callan’s opinions about quality control and alternate sources of BPA
27 is GRANTED. His other opinions, including the lab results, are not struck. He is also permitted
28 to testify that he was unable to review the suitability of WellPet’s BPA testing methodology, a

1 subject he is properly qualified to opine about. He is not permitted to offer the remaining opinions
2 in the paragraph quoted above.

3 **iii. Damages Experts**

4 Finally, WellPet moves to exclude the opinions of Zeiger’s damages experts, Colin Weir
5 and Steven Gaskin. *See* WellPet Strike Mot. 14. WellPet’s half-page argument on this point is
6 entirely derivative of its argument in opposition to class certification. *See id.* (“For the reasons set
7 forth in section I.B of WellPet’s opposition to Plaintiff’s motion for class certification...”).
8 Accordingly, I analyze the parties’ briefing on both motions.

9 Zeiger’s economic experts conducted a conjoint analysis. *See* Declaration of Colin B.
10 Weir (“Weir Rep.”) [Dkt. No. 163-9]; Expert Report of Steven P. Gaskin (“Gaskin Rep.”) [Dkt.
11 No. 163-10]. In that analysis, they surveyed a representative sample that measured respondents’
12 preferences for WellPet Products with and without each Wellness statement and with and without
13 the omission that heavy metals and BPA were in the products. Gaskin Rep. at 7–13. They then
14 determine the “price premium” that results to consumers. In other words, they determine how
15 much more a consumer is paying for a WellPet product with the presence of the Wellness
16 Statements and/or the absence of the omissions. Similar analyses are often examined in the
17 caselaw. *See, e.g., In re Volkswagen “Clean Diesel” Mktg., Sales Practices, & Prod. Liab. Litig.*,
18 No. 3:17-CV-4372-CRB, 2020 WL 6688912, at *7–*8 (N.D. Cal. Nov. 12, 2020); *Krommenhock*
19 *v. Post Foods, LLC*, 334 F.R.D. 552, 573–77 (N.D. Cal. 2020); *Hadley v. Kellogg Sales Co.*, 324
20 F. Supp. 3d 1084, 1103–07 (N.D. Cal. 2018).

21 “[A] model purporting to serve as evidence of damages in this class action must measure
22 only those damages attributable to” the plaintiff’s theory of liability. *Leyva*, 716 F.3d at 514
23 (quoting *Comcast*, 133 S. Ct. at 1435). And price premiums attributable to alleged
24 misrepresentations have been accepted, as a general matter, as valid measures for damages in these
25 cases. *See, e.g., Krommenhock*, 334 F.R.D. at 575; *Hadley*, 324 F. Supp. 3d at 1204 (collecting
26 cases). As a result, a “full refund” (that is, a price premium worth the same or more than the
27 actual price of the product) can only be given if the product is actually worthless to the consumer.
28 *See Krommenhock*, 334 F.R.D. at 578. In other words, “[a] full refund *may* be available in a UCL

1 case when the plaintiffs prove the product had *no* value to them.” *In re Tobacco Cases II*, 240
2 Cal. App. 4th 779, 795 (2015).

3 Zeiger’s damages model attempts to calculate the price premium associated with each
4 Wellness Statement and with the omissions. That price premium can be expressed as a percentage
5 of total price. Gaskin calculates the following price premiums for the Wellness Statements:
6 “natural” is 3.0 percent, uncompromising nutrition is 1.9 percent, “unrivaled quality standards” is
7 2.6 percent, “with nothing in excess and everything in balance” is 3.0 percent, and “complete
8 health” is 4.3 percent. Gaskin Rep. at 30–31. Gaskin also measures the price premiums of the
9 omission of lead and arsenic and the omission of BPA at 46.2 percent each. *Id.* at 31. He derives
10 these omission figures from the inclusion of the hypothetical disclosure “may contain measurable
11 amounts of heavy metals such as arsenic or lead” or “Bisphenol A (BPA).” *Id.*

12 All three Wellness Products always lack both omissions. Just the omissions, therefore, are
13 calculated at 92.4 percent of the value of the product. Each of the Wellness Products also always
14 contained some combination of Wellness Statements. Based on their percentages, the net result is
15 that two of the three products have price premiums that are more than 100 percent, and the third is
16 a few percentage points away. In other words, Gaskin values two of the three products as
17 worthless (in fact, worse than worthless) and the third as worth close to it.

18 Gaskin has produced a full refund model. Although Zeiger resists this characterization,
19 WellPet Strike Oppo. 18, the *end-result* of the analysis would be a full refund for two of the three
20 products and very close to it for the third if Zeiger’s theories were accepted at trial.³ The law is
21 clear that a full refund model is only justified when the plaintiffs prove the products have no value.
22 *See, e.g., Krommenhock*, 334 F.R.D. at 577–78 (“That model has been rejected by numerous
23 courts when proffered in consumer product cases where the product provided some value.”);
24 *Chowning*, 735 Fed. App’x at 925.

25 Zeiger attempts to justify this model by showing that the Wellness Products had no value
26 because they are allegedly unsafe. WellPet Strike Mot. 19–20. That is unpersuasive for two

27

28 ³ It is irrelevant that I have excluded the BPA opinions and, accordingly, that omission appears no longer at issue. The *result* of Gaskin’s analysis was still a full refund.

1 reasons. These consumers inarguably *did* get value from the Wellness Products. Their pets
2 consumed them and received nutrients from them. And even on Zeiger’s theory, there is no
3 evidence that any individual Wellness Product was a health risk. Instead, Zeiger’s argument is
4 that they cumulatively can be a health risk, and so need warnings. As a result, not every bag a
5 consumer ever purchased had zero value due to being dangerous in a way that, for instance, a
6 device that dangerously explodes might.

7 It is conceivable that the problems may have resulted from not revealing a sufficient
8 amount of information about arsenic, lead, and BPA to the survey participants. Perhaps survey
9 participants would give more accurate answers with more information about the substances and
10 about the extent to which other dog foods contain them. Maybe not. But it seems more than
11 possible for an analysis to sufficiently capture the price premium consumers paid due to the
12 Wellness Statements and omissions; there appears to be no barrier to some price being applied that
13 is sufficiently reliable and tied to the injury. This is a fairly standard case in terms of how one
14 might measure damages. As I explain below, I will deny the motion to certify a 23(b)(3) class
15 with leave to bring a renewed motion with a renewed damages model. Because it is unclear what
16 this model may look like, I do not rule on WellPet’s other arguments about the reliability of the
17 current model.

18 The motion is GRANTED IN PART and DENIED IN PART as described above.

19 **B. Zeiger’s Motion to Strike**

20 Zeiger moves to strike portions of the Declaration of Gregory G. Kean, WellPet’s Vice
21 President of Innovation and Product Development, that WellPet submitted in support of its
22 Opposition to class certification. *See* Plaintiff’s Motion to Strike Portions of Declaration of
23 Gregory G. Kean (“Zeiger Strike Mot.”) [Dkt. No. 171]. Zeiger argues that Kean was not
24 disclosed as an expert yet renders expert opinions; he also argues that Kean offers inadmissible
25 legal opinions.

26 **i. Preliminary Issues**

27 As an initial matter, WellPet argues that the motion should be rejected because it was not
28 made earlier. On September 29, 2020, the parties brought a discovery dispute to me. Dkt. No.

1 161. Zeiger argued that declarations of three new witnesses served by WellPet after the close of
2 fact discovery were untimely. *Id.* at 1–3. One of those was Kean. *Id.* Zeiger requested that the
3 declarations should be struck or he should be permitted to depose those witnesses again. *Id.* I
4 granted the request to depose the other two witnesses but denied the request to depose Kean,
5 finding that “Kean was adequately disclosed and plaintiffs had the opportunity during his Rule
6 30(b)(6) deposition to cover relevant topics.” Dkt. No. 164.

7 WellPet argues that this issue should have been addressed during that dispute. WellPet’s
8 Opposition to Zeiger Strike Mot. (“Zeiger Strike Oppo.”) [Dkt. No. 171] 1. I disagree. At the
9 time of that dispute, WellPet had not identified Kean as an expert. I made clear that I was denying
10 the request to depose him “as a fact witness.” Dkt. No. 164. Now that class certification briefing
11 has occurred, Zeiger has seen how Kean’s opinions are being used and argues that they are being
12 used as improper expert opinion.

13 Relatedly, WellPet argues that it would be unfairly prejudiced by striking these opinions
14 now because it is after WellPet has submitted its brief and expert declarations, and after I denied it
15 an extension to file its class certification Opposition in light of the discovery dispute discussed
16 above. *Id.* 2.⁴ WellPet is no more prejudiced than any other party facing a motion to strike
17 resolved at the same time as a substantive underlying motion. WellPet itself filed a *Daubert*
18 motion about four of Zeiger’s experts. If WellPet *had* disclosed Kean as an expert, he would be
19 subject to such a motion today. Because WellPet did not, it is fair for Zeiger to move to strike and
20 for WellPet to oppose that motion.

21 **ii. Expert Opinions**

22 Federal Rule of Civil Procedure 26(a)(2) governs disclosure of expert testimony. It
23 provides that each party “must disclose to the other parties the identity of any witness it may use at
24

25 ⁴ On September 28, 2020, WellPet requested (prior to filing the discovery dispute) an extension
26 for class certification deadlines until after any new depositions were taken pursuant to the
27 discovery order discussed above. Dkt. No. 157. I denied that motion, explaining that I would
28 “address the joint letter regarding the disputed depositions when it is filed, but defendant has not
explained why the depositions sought from its witnesses (and not yet granted) would cause it
cognizable prejudice.” Dkt. No. 159. I then ruled on the discovery dispute the day after it was
filed.

1 trial to present evidence under Federal Rule of Evidence 702, 703, or 705,” the rules governing
2 expert testimony. Fed. R. Civ. P. 26(a)(2)(A). This disclosure must conform to Rule 26(a)(2)(B),
3 which imposes a series of requirements, including “a complete statement of all opinions the
4 witness will express and the basis and reasons for them,” “the facts or data considered by the
5 witness,” and “the witness’s qualifications.” These disclosures ensure that each party is able to
6 adequately assess and challenge the expert’s opinions. Under Rule 26(a)(2)(D), “[a] party must
7 make these disclosures at the times and in the sequence that the court orders. Absent a stipulation
8 or a court order, the disclosures must be made: (i) at least 90 days before the date set for trial or for
9 the case to be ready for trial; or (ii) if the evidence is intended solely to contradict or rebut
10 evidence on the same subject matter identified by another party under Rule 26(a)(2)(B) or (C),
11 within 30 days after the other party’s disclosure.” Rule 37(c)(1) provides an enforcement
12 mechanism: “If a party fails to provide information or identify a witness as required by Rule 26(a)
13 or (e), the party is not allowed to use that information or witness to supply evidence on a motion,
14 at a hearing, or at a trial, unless the failure was substantially justified or is harmless.”

15 The determination of whether testimony is lay or expert is governed by the Federal Rules
16 of Evidence. The definitions of lay and expert opinions are mutually exclusive. Lay opinions are,
17 among other things, “not based on scientific, technical, or other specialized knowledge within the
18 scope of Rule 702.” Fed. R. Evid. 701(c). Expert opinions must be based on “the expert’s
19 scientific, technical, or other specialized knowledge.” Fed. R. Evid. 702(a).

20 The mere fact that knowledge is particularized does not necessarily make it an improper
21 subject for lay opinion. The notes of the advisory committee to Rule 701 discuss the admissibility
22 of opinions based on “particularized knowledge that the witness has by virtue of his or her
23 position in the business.” Fed. R. Evid. 701 advisory committee’s notes to the 2000 amendment.
24 The typical example is “the owner or officer of a business [being permitted] to testify to the value
25 or projected profits of the business, without the necessity of qualifying the witness as an
26 accountant, appraiser, or similar expert.” *Id.* Many courts have therefore permitted particularized
27 business knowledge under Rule 701. *See In re Google AdWords Litig.*, No. 5:08-CV-3369 EJD,
28 2012 WL 28068, at *4 (N.D. Cal. Jan. 5, 2012) (surveying cases), *rev’d and remanded on other*

1 *grounds sub nom. Pulaski & Middleman, LLC v. Google, Inc.*, 802 F.3d 979 (9th Cir. 2015).

2 Kean was not adequately disclosed as an expert. There was no timely expert disclosure
3 about him that met the standard set out in Rule 26(a)(2)(B) despite WellPet’s disclosures of
4 several other experts. In 2018, Kean was deposed as a Rule 30(b)(6) witness for WellPet. His
5 current duties “involve development of new products, maintaining the nutritional integrity of
6 WellPet’s products, regulatory compliance, quality assurance, technical services, and
7 commercialization.” Kean Decl. ¶ 1.

8 Zeiger objects to two types of testimony from Kean. First, Kean discusses the Association
9 of American Feed Control Officials (“AAFCO”), a voluntary association of animal food and drug
10 regulators. *Id.* ¶¶ 11–14. Applying the framework discussed above, some of Kean’s statements
11 about AAFCO are proper lay witness testimony and some that could only be properly made by an
12 expert. Kean may describe AAFCO and its role, *see* Zeiger Strike Mot. 4 (objecting to this),
13 because that requires no specialized knowledge. Kean Decl. ¶ 11. His testimony on this may, like
14 any others, be attacked on other proper grounds. Kean may also report the AAFCO’s definition of
15 “natural,” *id.* ¶ 13, and his understanding of how AAFCO guidance is promulgated, *id.* ¶ 12.

16 Kean may not opine that WellPet’s products “satisfy the AAFCO definition of ‘natural.’”
17 *Id.* ¶ 14. To reach that conclusion, Kean must opine about how WellPet’s ingredients are
18 “derived” and “mined”; about their chemical composition, including “trace amounts” of heavy
19 metals and chemicals he labels as naturally occurring; and about the prevalence of those
20 substances in the environment. *Id.* All of that is plainly specialized knowledge that requires
21 expertise. Indeed, these types of issues are the subject of other expert evidence in this case.

22 WellPet responds that these opinions are the result of Kean’s “particularized knowledge”
23 taken from his job responsibilities. That doctrine does not transform expert evidence into lay
24 evidence. The Advisory Committee has explained that “[s]uch opinion testimony is admitted *not*
25 because of experience, training or specialized knowledge within the realm of an expert, but
26 because of the particularized knowledge that the witness has by virtue of his or her position in the
27 business.” Fed. R. Evid. 701 advisory committee notes to the 2000 amendment. This
28 particularized knowledge rule recognizes that some particularized knowledge is within the ken of

1 laypeople simply from performing their jobs. The rule does not stand for the proposition that
 2 *merely* because knowledge is acquired on the job it is always admissible as lay opinion. Here,
 3 although Kean may have acquired this knowledge during the course of his job, the opinions
 4 themselves cross the line into “scientific, technical, or other specialized knowledge.” They—but
 5 not the other evidence discussed above—will be struck.

6 Second, Zeiger objects to testimony about heavy metals and BPA in five paragraphs of the
 7 declaration. Kean is permitted to testify to “factual information about WellPet’s position on the
 8 safety of BPA.” Zeiger Strike Oppo. 6. Kean may also, again, report on various AAFCO
 9 requirements that he believes WellPet adheres to. *See* Kean Decl. ¶ 26. So long as he is merely
 10 *reporting* regulatory guidance, he may state that the FDA has not identified heavy metals as a
 11 “risk for kibble generally” or “identified BPA as a risk for pet food.” *Id.* ¶¶ 27, 40. Zeiger may
 12 attempt to impeach him about these conclusions but they do not require specialized knowledge
 13 within the meaning of FRE 702.

14 Kean may not, however, opine that “[i]t is not technically possible to eliminate all trace
 15 amounts of arsenic and lead from the Products,” *id.* ¶ 39, or that “eliminating all trace amounts
 16 from the Products is not technically possible,” *id.* ¶ 43. For substantially the reasons set out
 17 above, those are expert opinions thinly veiled as a lay witness’s knowledge acquired from
 18 business. Whether it is “technically” possible to eliminate certain chemicals from products is a
 19 technical and specialized opinion. Indeed, in its co-pending *Daubert* motion, WellPet argues that
 20 the inverse opinion cannot be made by Zeiger’s *expert* because that expert is a nutritionist and not
 21 a toxicologist, and therefore insufficiently specialized. Even if this evidence were acquired during
 22 the course of Kean’s job duties, it is still expert knowledge.

23 WellPet also argues that, if I determine any of these opinions are expert in nature, they
 24 should not be struck. Zeiger Strike Oppo. 7–8. It first relies on the Ninth Circuit’s decision in
 25 *Sali v. Corona Regional Medical Center* for the principle that “[i]nadmissibility alone is not a
 26 proper basis to reject evidence submitted in support of class certification.” 909 F.3d 996, 1004
 27 (9th Cir. 2018); Zeiger Strike Oppo. 7. That principle comes from a line of cases holding that
 28 class certification motions need not be decided by “the formal strictures of trial.” *Id.* WellPet’s

1 reliance on this line of cases is misplaced. The issue here is not that evidence will ultimately be
2 *admissible* at the merits stage, it is that Kean was not *disclosed* as an expert. That determination
3 happens to turn on an issue governed by the Rules of Evidence, but the ultimate conclusion is that
4 WellPet failed to disclose Kean as an expert and so cannot use him as one going forward.

5 Finally, WellPet argues that there is no prejudice in permitting Kean to testify as an expert
6 because he “was identified as a potential witness in interrogatory responses, documents were
7 produced from his custodial files, and a full-day deposition was conducted.” Zeiger Strike Oppo.
8 7. The prejudice to Zeiger is clear. If Kean had been properly disclosed as an expert, Zeiger
9 would have been given a full Rule 26 disclosure; could have questioned Kean as an expert, rather
10 than as a corporate representative as occurred in reality; could have determined whether its own
11 experts needed to rebut any of Kean’s expert opinions; and could have filed a *Daubert* motion to
12 do so. Allowing Kean’s improper opinions and denying this motion to strike, in contrast, would
13 mean that Kean could testify to expert opinions without having gone through any of the hurdles
14 that other experts do.⁵

15 **iii. Legal Opinions**

16 Zeiger moves to strike the opinions in four paragraphs of Kean’s Declaration as “improper
17 legal opinions.” *See* Zeiger Strike Mot. 6–7.

18 “[A]n expert witness cannot give an opinion as to her legal conclusion, i.e., an opinion on
19 an ultimate issue of law. Similarly, instructing the jury as to the applicable law is the distinct and
20 exclusive province of the court.” *Nationwide Transp. Fin. v. Cass Info. Sys., Inc.*, 523 F.3d 1051,
21 1058 (9th Cir. 2008). Even when this type of testimony is offered as lay opinion, “the district
22 court could exclude it because the testimony [i]s not helpful to a clear understanding of the
23 testimony or a fact in issue.” *Id.* at 1059 (internal quotation marks omitted). This is because

24
25 _____
26 ⁵ Nor is it sufficient that Kean “provided his education and experience in his declaration, which
27 was served on Plaintiff at the same time as WellPet’s expert reports . . . [and] included citations to
28 any materials he consulted for his declaration.” Zeiger Strike Oppo. 8. That is far from the robust
expert disclosure—not to mention time and opportunity to prepare and rebut—that the Rules
require. Similarly, that Kean was deposed as a fact witness, *id.*, is of no moment because this new
declaration includes expert opinions that could not reasonably have been anticipated from a non-
expert corporate representative.

1 applying law (in that case, the Uniform Commercial Code) to facts is to “instruct the jury
2 regarding how it should decide” the legal question and such testimony is not “helpful” as it must
3 be under FRE 701. *Id.* at 1059–60. District courts may, accordingly, preclude witnesses from
4 relating legal conclusions, but not the facts underpinning those conclusions (so long as they are
5 otherwise admissible). *Id.* at 1060.

6 In paragraph 11, Kean opines that “[t]he packaging for the Products complies with the
7 model pet food regulations established by the Association of American Feed Control Officials
8 (“AAFCO”) and endorsed by FDA.” Kean Decl. ¶ 11. In paragraph 19, Kean states that “WellPet
9 is fully compliant with the FDA Food Safety Modernization Act (“FSMA”) across our products.”
10 *Id.* ¶ 19. These are legal conclusions; that is, they require an application of the standard set out in
11 regulatory guidance or government-endorsed model regulations to particular facts. WellPet
12 characterizes Kean as merely having “read the relevant documents and stated WellPet’s position
13 that it has complied.” Zeiger Strike Oppo. 6. While Kean may state the *facts* underlying his view
14 on compliance—so long as they are otherwise admissible—he may not do what he has done here,
15 which is reach legal conclusions. This conclusion is not altered by the fact that Kean’s “job
16 responsibilities” include regulatory compliance. He is not testifying as a regulatory expert but as a
17 lay witness. And it is unhelpful to the jury to hear a lay witness apply legal standards to particular
18 facts.

19 In paragraph 25, Kean states, “[u]nder [the FDA’s] risk-based approach to food safety, pet
20 food manufacturers only need to apply preventive controls if, after conducting a hazard analysis of
21 each type of animal food manufactured, they determine that there are known or reasonably
22 foreseeable [sic] biological, chemical, or physical hazards, and those hazards require a preventive
23 control. *See* 21 C.F.R. §§ 507.33, 507.34.” *Id.* ¶ 25. This too is a legal opinion. Indeed, it goes
24 beyond the conclusory opinions discussed above because it purports to interpret and boil down the
25 FDA’s regulatory scheme. That is not the province of a lay corporate witness.

26 In paragraph 38, Kean states,

27 WellPet determined from these test results that the fish ingredients do not pose a risk in the
28 company’s products, and, as a result, further testing of fish-based ingredients, either by
suppliers or by WellPet, was not necessary. This is consistent with the regulations FDA

1 subsequently issued in 2015, which state that only when a substance is determined to be a
2 hazard, and a hazard that requires a preventive control, does the manufacturer need to
3 identify and implement preventive controls for that substance. *See* 21 C.F.R. §§ 507.33,
4 507.34.

5 *Id.* ¶ 38. I agree that the portion of this opinion purporting to show consistency with FDA
6 regulations—and interpreting them—is not admissible for the reasons already discussed. The first
7 sentence, however, is admissible on this ground to the extent it simply relates what WellPet did or
8 determined.

9 The motion is GRANTED IN PART and DENIED IN PART as described above.

10 **II. MOTION FOR SUMMARY JUDGMENT**

11 WellPet moves for summary judgment on all of Zeiger’s (individual) claims. *See*
12 WellPet’s Motion for Judgment on the Individual Claims of Daniel Zeiger (“SJ Mot.”) [Dkt. No.
13 180].

14 **A. Safety of Arsenic, Lead, and BPA in the Wellness Products**

15 **i. Arsenic and Lead**

16 WellPet first contends that Zeiger cannot show that the amounts of arsenic, lead, and BPA
17 in the Wellness Products are a health risk to dogs. I disagree.

18 Zeiger has demonstrated a genuine dispute of material fact about the dangerousness of the
19 amounts of arsenic and lead that can occur in the Wellness Products. As explained above, Pusillo
20 (Zeiger’s expert) opines that lead and arsenic can “bioaccumulate” in dogs. Consequently, even
21 the small amounts alleged to be in the Wellness Products would be unsafe if the Products were
22 consumed over a sufficient time by a dog. At summary judgment, the admissible opinion of an
23 expert on this issue is sufficient to create a genuine dispute of material fact.

24 WellPet’s argument to the contrary primarily rested on its *Daubert* motion. Aside from
25 that, it first points to *Lucido*. SJ Mot. 10–11. There, as previously explained, the court excluded
26 the proffered expert’s opinion. *Lucido*, 217 F. Supp. 3d at 1107–08. Here, in contrast, Pusillo’s
27 opinion survives *Daubert*. There, too, there was no bioaccumulation theory. *Lucido*’s conclusion
28 that there was no evidence that small amounts of mycotoxins were harmful made sense: on that
record there was no longer any such evidence. Here, because of the bioaccumulation theory, there

1 is.

2 Nor is the dispute avoided because lead and arsenic are “naturally occurring” or
3 “ubiquitous” in the environment. SJ Mot. 10–11. Pusillo’s bioaccumulation theory introduces a
4 genuine dispute of material fact about their dangerousness; the debate about ubiquity is beside the
5 point. Merely because a substance is “naturally occurring” or impossible to *entirely* remove from
6 the food supply as a whole does not necessarily mean that it is safe in any quantity, nor does it
7 necessarily mean there is not a duty to disclose it under California law. As the FDA posts that
8 WellPet cites make clear, arsenic and lead are to be limited to the extent feasible. Moreover, this
9 is not a case about regulatory compliance; as a matter of California consumer protection law, the
10 extent to which the substances are pervasive is only relevant in that the jury will take it into
11 account when determining what a reasonable consumer would believe.

12 Relatedly, WellPet puts forward evidence—such as guidance from the FDA, European
13 Union regulators, and scientific groups—that Pusillo is wrong and that the relevant amounts of
14 lead and arsenic have not been shown to be harmful for dogs. But this case is at summary
15 judgment. Zeiger has submitted competent, admissible evidence to support his theory; it would be
16 improper for me to weigh that evidence against WellPet’s evidence. Much of WellPet’s argument
17 on this point is not for summary judgment, it is for trial or a *Daubert* motion. *See, e.g.*, SJ Mot. 12
18 (“Dr. Pusillo’s opinions are contrary to the findings of the expert scientists at the NRC, FDA, and
19 European Commission, yet he makes no effort to address this contrary evidence.”).

20 Although that settles the issue on this motion, I note that WellPet’s evidence is not quite as
21 conclusive as it asserts. Among other things, it presents no definitive evidence showing that the
22 bioaccumulation theory is not physically possible. Additionally, as alluded to, many of the FDA
23 materials that WellPet relies on are either nonbinding guidance, posts online, or are less conclusive
24 than WellPet contends.

25 **ii. BPA**

26 WellPet is entitled to summary judgment that the presence of the alleged amounts of BPA
27 in its Wellness Products does not pose a health risk to dogs. SJ Mot. 13–14. As explained earlier,
28 Pusillo’s opinion on BPA is excluded under *Daubert*. He did not opine that BPA bioaccumulates.

1 WellPet has submitted an expert report (that has not been challenged under *Daubert*) that opines
2 that there is no risk to dogs of the levels of BPA purported to be present in the Wellness Products.
3 Poppenga Rep. at 17–18. Zeiger’s reply is only that it is a “battle of the experts as WellPet simply
4 disagrees with Dr. Pusillo’s findings.” Plaintiff’s Opposition to WellPet’s SJ Mot. (“SJ Oppo.”)
5 [Dkt. No. 189] 13. Without Pusillo’s findings, Zeiger cannot introduce a genuine dispute of
6 material fact about the safety of BPA at these levels in dog food.

7 **B. Whether the Statements and Omissions are Misleading**

8 The core of WellPet’s motion for summary judgment is that there is not, as a matter of law,
9 anything misleading about its packaging. SJ Mot. 14–17. Although Zeiger brings both
10 misrepresentation- and warranty-based claims, they all revolve around the same alleged
11 misrepresentations and omissions.

12 Claims under the UCL, FAL, and CLRA are, at this stage, generally governed by the same
13 reasonable consumer test. *Ebner v. Fresh, Inc.*, 838 F.3d 958, 965 (9th Cir. 2016); *Williams v.*
14 *Gerber Prod. Co.*, 552 F.3d 934, 938 (9th Cir. 2008). Under that test, Zeiger will ultimately have
15 to show that “members of the public are likely to be deceived.” *Id.*; *Kasky v. Nike, Inc.*, 27 Cal.
16 4th 939, 951 (2002), *as modified* (May 22, 2002). “Whether a practice is deceptive, fraudulent, or
17 unfair is generally a question of fact which requires consideration and weighing of evidence from
18 both sides.” *Linear Tech. Corp. v. Applied Materials, Inc.*, 152 Cal. App. 4th 115, 134–35 (2007)
19 (internal quotation marks omitted). Materiality is for the jury “unless the fact misrepresented is so
20 obviously unimportant that the jury could not reasonably find that a reasonable man would have
21 been influenced by it.” *In re Tobacco II Cases*, 46 Cal. 4th 298, 327 (2009) (internal quotation
22 marks omitted).

23 Zeiger brings claims based both on the Wellness Statements (allegedly misleading
24 affirmative statements) and based on WellPet’s omission of the inclusion of lead, arsenic, and
25 BPA. WellPet focuses exclusively on the Wellness Statements. Because WellPet does not move
26 for summary judgment on the pure omissions claims, they survive.

27 As an initial matter, WellPet argues that the Wellness Products “do not claim to be free
28 from *any* heavy metals or BPA.” SJ Mot. 15 (internal quotation marks and alterations omitted).

1 That is true; Wellness Products have no explicit claim that they lack these substances. But that is
2 not Zeiger’s theory nor what a claim like this requires. Zeiger contends that the Wellness
3 Statements are *misleading*, not that there is an *explicit* guarantee. Again, those statements are (1)
4 “uncompromising nutrition,” (2) nothing in excess and everything in balance,” (3) “complete
5 health,” (4) “natural,” and (5) “unrivalled quality standards.” WellPet relies on *Simpson v.*
6 *Champion Petfoods USA, Inc.*, for this point, but the portion it cites concerned whether certain
7 statements on the packaging were partial representations that triggered a failure to disclose which,
8 at least in California, requires that a statement be *contrary* to the omitted information. *Simpson*,
9 397 F. Supp. 3d 952, 972–73 (E.D. Ky. 2019); *see Hodsdon v. Mars, Inc.*, 891 F.3d 857, 861 (9th
10 Cir. 2018) (discussing partial representations). Here, the issue is whether the statements are
11 misleading, not explicitly contrary.⁶

12 Summary judgment on these statements would be improper. How a reasonable consumer
13 would understand them is a quintessential matter for a jury. *Linear Tech.*, 152 Cal. App. 4th at
14 134–35. A statement like “uncompromising nutrition” might simply be understood to mean that
15 the Wellness Products were highly nutritious compared to other possible dog food formulations.
16 But, viewed in the light most favorable to Zeiger, it might also be reasonably understood to mean
17 that non-nutritious substances will not exist in the dog food—that is, it is “uncompromising.”
18 Similarly, “unrivalled quality standards” might be understood as a marketing platitude, or it might
19 be understood to communicate that steps are taken to ensure quality control in ingredients that
20 could, among other things, include elimination of heavy metals or synthetic chemicals.

21 The argument is even stronger for “natural,” which is likely to have a more concrete
22 meaning to reasonable consumers. I note, however, that the natural representation may not be

23
24 ⁶ *Song v. Champion Petfoods USA, Inc.*, No. 18-CV-3205 (PJS/KMM), 2020 WL 7624861 (D.
25 Minn. Dec. 22, 2020), was decided since briefing closed here. In that case, the court held that a
26 number of statements on dog food bags (though not statements identical to those here) would not
27 mislead reasonable consumers. There, however, the court was explicit that “plaintiffs do not
28 allege that Champion’s dog food contains heavy metals in amounts that may harm dogs” and so
held one of the statements could not be misleading on that basis. *Id.* at *5. The second statement
did not concern arsenic, lead, or BPA. *Id.*, at *8–*9. And the third set of statements were held to
be non-actionable puffery, an argument not before me. *Id.*, at *9–*10. Accordingly, the only
determination on lead and arsenic failed for the same reason as in *Lucido*: unlike here, there was
no evidence of a health risk.

1 sustainable on the basis of lead and arsenic alone, because they are alleged (unlike BPA) to be
2 naturally occurring. The parties have had no chance to address this issue in light of my ruling on
3 the admissibility of the BPA opinions today, so it may be dealt with by motion in limine.

4 Additionally, Zeiger has retained an advertising expert whose opinions have not been the
5 subject of a *Daubert* motion. See Report of Bruce G. Silverman (“Silverman Rep.”) [Dkt. No.
6 151-6]. That expert examined each of the Wellness Statements and determined, based on his
7 expertise in consumer understanding and brand development, that each would be understood by
8 consumers to communicate that the products were healthy and safe. WellPet attacks his opinions
9 but has not moved to exclude them under *Daubert*, so its attacks go to their weight. SJ Mot. 17–
10 18. And although it seeks to cast the opinions as speculative, their methodology has not been
11 challenged under the Federal Rules of Evidence and they are proffered as the product of extensive
12 experience in advertising. A jury may agree or disagree about what a reasonable consumer would
13 believe, but the advertising expert’s opinions are relevant and helpful.

14 WellPet has several responses. It contends that the context in which the Wellness
15 Statements appear entitles it to summary judgment. SJ Mot. 15–16. It argues that:

16 The surrounding text on the packaging itself explains what the statements mean. For
17 example, the phrase “uncompromising nutrition” has appeared next to a block of text on
18 the CORE Ocean packaging explaining that the product is “based on the nutritional
19 philosophy that dogs, given their primal ancestry, thrive on a diet mainly comprised of
20 meat,” the product is “nutrient-dense,” and “packed with a high concentration of quality
21 animal protein, without fillers or grains, along with a proprietary blend of botanicals and
22 nutritional supplements.”

23 SJ Mot. 15.

24 WellPet may be correct that a reasonable consumer would understand the surrounding
25 packaging to clarify these statements, but I cannot so hold on summary judgment. A reasonable
26 consumer might also understand the more prominently placed Wellness Statements to be broader,
27 not narrowed by other specific phrases on the packing. Agreeing with WellPet would require me
28 to transform summary judgment into a highly contextual analysis that made assumptions about
how consumers experience packaging. At this point, WellPet’s views on how a consumer would
understand these phrases are unsupported speculation; it has offered no evidence that any

1 consumer would actually understand them this way, in contrast to Zeiger’s expert evidence.

2 This argument of WellPet’s, additionally, is to some extent undermined by its position in
3 class certification that the packaging of its products varies so much that common questions do not
4 predominate. While WellPet argues in class certification that all of its packaging cannot possibly
5 be determined to be misleading as a whole, it argues here that the packaging is sufficiently
6 uniform that I can determine that it is not misleading as a matter of law.

7 WellPet also falls back to its argument that arsenic, lead, and BPA are ubiquitous and
8 cannot be removed entirely from the food supply. First, that does not mean that they cannot be
9 removed from this particular dog food, as Zeiger’s expert opines. Second, it would be improper to
10 determine at summary judgment whether a reasonable consumer would be misled by the Wellness
11 Statements despite the alleged prevalence of these substances.

12 WellPet contends that not granting summary judgment would open the floodgates to
13 require labelling of virtually all pet food and much of the human food supply. It cites *Lucido* and
14 several other cases for the proposition such as, “every manufacturer would be required to disclose
15 that their products contain heavy metals or be barred from making any assertion of quality about
16 the products.” *Loeb v. Champion Petfoods USA Inc.*, 359 F. Supp. 3d 597, 605 n.7 (E.D. Wis.
17 2019); *see also Weaver v. Champion Petfoods USA Inc.*, 2020 WL 3847248, at *3 (E.D. Wis. July
18 8, 2020). But WellPet does not have evidence fit for summary judgment that this broad claim is
19 categorically true. A substance’s existence in the food supply *as a whole* is quite different from it
20 being in all food. The removability of these substance is currently a matter of expert debate, as
21 discussed above. Moreover, this case concerns viable *health and safety* claims, not just nutritional
22 ones as in *Lucido*. Further, WellPet’s parade of horrors seems exaggerated. If a jury found
23 WellPet liable, that could presumably be remedied by a simple disclosure about lead and arsenic.
24 Most fundamentally, there is no authority from California courts or the Ninth Circuit holding that
25 there is an exception to the UCL, FAL, and CLRA just because the resulting disclosure would be
26 widespread or that the potentially dangerous substance is pervasive.

27 The parties also engage in a subsidiary dispute over whether WellPet previously concluded
28 that arsenic, lead, or BPA were a health risk. That debate is immaterial for present purposes

1 because no summary judgment determination turns on it.

2 **C. Reliance**

3 WellPet argues that there is no evidence that Zeiger relied on the Wellness Statements or
4 omissions. SJ Mot. 19–20. Zeiger does not dispute that he must show reliance on the
5 misrepresentations. *See Sandoval v. PharmaCare US, Inc.*, 730 F. App’x 417 (9th Cir. 2018)
6 (requiring actual reliance for UCL, CLRA, FAL, and warranty claims). *But see Bradach v.*
7 *Pharmavite, LLC*, 735 F. App’x 251, 254 (9th Cir. 2018) (“Under California law, class members
8 in CLRA and UCL actions are not required to prove their individual reliance on the allegedly
9 misleading statements. Instead, the standard in actions under both the CLRA and UCL is whether
10 members of the public are likely to be deceived.”). He presented enough evidence to create at
11 least a genuine dispute of material fact.

12 First, to adequately show reliance in a pure omission case, Zeiger need not point to any
13 particular past *statement* on which he relied. “To prove reliance on an omission, a plaintiff must
14 show that the defendant’s nondisclosure was an immediate cause of the plaintiff’s injury-
15 producing conduct. A plaintiff need not prove that the omission was the only cause or even the
16 predominant cause, only that it was a substantial factor in his decision. A plaintiff may do so by
17 simply proving that, had the omitted information been disclosed, one would have been aware of it
18 and behaved differently.” *Daniel v. Ford Motor Co.*, 806 F.3d 1217, 1225 (9th Cir. 2015).

19 Zeiger has done so. The mechanism for disclosure is WellPet’s packaging, which Zeiger
20 would have seen when buying products. The presence of lead and arsenic are, on Zeiger’s theory,
21 material because of the safety threat they pose. WellPet counters that Zeiger made a series of
22 statements in his deposition to the effect that lead and arsenic are naturally occurring and that trace
23 amounts will exist in all substances, including pet food. SJ Mot. 20 (collecting examples). It is
24 not clear that Zeiger was testifying to what he knew at the time of the purchases, as opposed to
25 what he learned during the course of this suit. Because this case is on summary judgment, I must
26 draw the reasonable inference in Zeiger’s favor that he was unaware (as most consumers
27 presumably are) of these issues at the time. It will be up to a jury to determine whether Zeiger was
28 aware of information that would have meant that he did not rely on the omissions.

1 Turning to the Wellness Statements, Zeiger testified that the “natural” mattered to him
2 when buying it. *See, e.g.*, Dkt. No. 172-8 at 38:10–14 (“Q. Were those both reasons for why you
3 started buying WellPet product, that they had a nice package and the word “Wellness®”? A. And
4 it looked like wholesome, you know, natural ingredients on it.”); 52:11–23 (“Q. What -- what
5 leads you to conclude that -- that it seemed like a superior product when you first bought it? A.
6 All their claims on -- you know, on the packaging and from the people that this is all natural, from
7 the earth, you know, better quality than you can get from regular dog food.”); 51:14–23 (“And it --
8 it touted everything. It’s -- on the bag it says only the finest ingredients. You know, it’s all
9 natural, highest quality.”).

10 WellPet says that Zeiger testified that he does not believe products that claim to be natural.
11 WellPet’s Reply in Support of SJ Mot. (“SJ Reply”) [Dkt. No. 193] 9. But the portion of his
12 deposition it relies on is ambiguous. Zeiger was asked, “Have you ever sought out the definition
13 of natural, as used by industry or regulators?” He answered, “No. I think it’s gotten clouded in
14 the past years from what it probably was back in the ‘70s. So I don’t know -- yeah, I don’t put my
15 faith when something says it’s natural. I look -- try to look a little further, but there’s only so far
16 you can look.” Dkt. No. 162-16 at 35:11–21. “[T]ry[ing] to look a little further” than the face
17 value of a claim because of a belief that such claims may be overhyped is distinct from not relying
18 on that claim at all. Given Zeiger’s representations that he did see and rely on the natural claim
19 and imagery, summary judgment cannot be granted on this point.

20 The evidence of reliance on the other Wellness Statements is more mixed. I conclude that
21 Zeiger has adequately shown genuine disputes of material fact about his reliance on them. As
22 noted above, he testified that what mattered to him about WellPet revolved around it being high-
23 quality, nutritious, and healthy. Those understandings would likely come from, among other
24 things, the Wellness Statements, which are all to that effect. WellPet’s position is apparently that
25 Zeiger is required to remember each particular misleading statement and have individually relied
26 on it. But the question is whether a reasonable consumer would be misled and whether that
27 misleading impression was a substantial factor in the choice to purchase. Because these
28 statements were all geared toward the same message and would potentially be (as explained

1 above) material to reasonable consumers, Zeiger had, at most, to show genuine disputes of
2 material fact about exposure and materiality, which he has.

3 **D. Damages and Restitution**

4 WellPet next argues that Zeiger cannot prove damages or establish that he is entitled to
5 restitution under California law. SJ Mot. 21–23. WellPet makes two related arguments. First, it
6 contends that because the Weir/Gaskin damages model is inadmissible, damages cannot be
7 measured. Second, it argues that Zeiger cannot adequately show damages because he cannot
8 remember what WellPet products he purchased or when and because he also purchased those
9 products for his business, which is excluded from his claims.

10 Because the damages model is inadmissible, I agree that Zeiger cannot show what level of
11 damages or restitution he is entitled to.

12 Apparently as a fallback position, Zeiger argues that he can show what he is owed
13 regardless of the admissibility of the Weir/Gaskin analysis. SJ Oppo. 22–23. He relies on (1) his
14 testimony that he could have bought other food for “half” the price of WellPet and (2) WellPet’s
15 own documents illustrating the price premium over lower quality dog foods. Neither of these,
16 however, is a measure of what Zeiger would have paid *for the products absent the alleged*
17 *misrepresentations or omissions*, which is the standard. *Hadley*, 324 F. Supp. 3d at 1103. That
18 Zeiger could have bought some other dog food for half the price does not mean that dog food is
19 comparable. (That dog food may also have included arsenic, lead, or BPA in comparable levels,
20 meaning he would not have bought it either had it contained appropriate disclosures.) The
21 WellPet documents that Zeiger relies on do not show the price premiums *associated with the*
22 *alleged misrepresentations and omissions*, they merely show the price (in foreign, not U.S.,
23 markets) of high-quality, natural dog food over the lower quality alternatives.⁷

24
25
26 ⁷ I am granting leave for class certification to be renewed on the issue of damages. If a new
27 damages model is accepted, Zeiger has leave to file a motion for reconsideration on this part of the
28 order. See Civ. L.R. 7-9(a). The motion and opposition shall be limited to 10 pages; the reply
limited to 6.

1 **E. Equitable Relief**

2 WellPet asserts that Zeiger has an adequate remedy at law and so cannot seek equitable
3 relief, including an injunction. SJ Mot. 23. It also argues he lacks standing to pursue an
4 injunction. *Id.* 24.

5 **i. Adequate Remedy at Law**

6 In *Sonner v. Premier Nutrition Corporation*, the Ninth Circuit held that “federal courts
7 must apply equitable principles derived from federal common law to claims for equitable
8 restitution under” the UCL and CLRA. 971 F.3d 834, 837 (9th Cir. 2020). That holding, the
9 Ninth Circuit explained, flowed from the general principle that “a federal court must apply
10 traditional equitable principles before awarding restitution,” an equitable remedy. *Id.* at 841. One
11 well-established equitable principle is that equitable remedies will not be awarded when there is an
12 “adequate remedy at law.” *Id.* at 842.

13 *Sonner* concerned equitable restitution. WellPet argues that *Sonner* applies equally well to
14 injunctive relief because it too is equitable and that Zeiger has not shown that he lacks adequate
15 remedies at law. Zeiger responds that *Sonner* does not apply to injunctive relief and that, in any
16 event, Zeiger has shown a lack of adequate legal remedies. One court in this District and several
17 courts in California have held that it applies to injunctive relief. *See In re MacBook Keyboard*
18 *Litig.*, No. 5:18-CV-02813-EJD, 2020 WL 6047253, at *3 (N.D. Cal. Oct. 13, 2020) (collecting
19 cases).

20 Assuming that *Sonner* applies to injunctive relief, Zeiger has shown that monetary
21 damages for past harm are an inadequate remedy for the future harm that an injunction under
22 California consumer protection law is aimed at. Zeiger’s remedy at law, damages, is retrospective.
23 An injunction is prospective. Damages would compensate Zeiger for his past purchases. An
24 injunction would ensure that he (and other consumers) can rely on WellPet’s representations in the
25 future. *See, e.g., McGill v. Citibank, N.A.*, 2 Cal. 5th 945, 955 (2017) (explaining that UCL,
26 CLRA, and FAL injunctive relief is designed to prevent “future harm”). Accordingly,
27 retrospective damages are not an adequate remedy for that prospective harm.

28 *Sonner’s* holding was based on application of traditional federal equitable principles. *See,*

1 *e.g.*, *Sonner*, 971 F.3d at 841. The core equitable rule is that simply having *any* remedy at law is
2 not sufficient to foreclose equitable relief; instead, the remedy must be *adequate*. The Supreme
3 Court has often affirmed that retrospective money damages play a markedly different role than
4 prospective injunctive relief. *See, e.g.*, *Milliken v. Bradley*, 433 U.S. 267, 288–90 (1977)
5 (explaining that retrospective damages are generally not permitted under *Ex Parte Young* but
6 prospective remedies, including injunctions, generally are).

7 As a result, it makes sense that *Sonner* may sometimes bar equitable *restitution* when
8 damages are available because, as in *Sonner* itself, equitable restitution may seek to compensate a
9 plaintiff for the same past harm as monetary damages. *Sonner*, 971 F.3d at 841. Similarly, it has
10 long been true that the availability of monetary damages forecloses injunctive relief of certain
11 types. The classic example is that specific performance (via injunction) of a contract will not be
12 ordered unless damages are insufficient. *See* Restatement (Second) of Contracts § 359(1). But, at
13 least on the facts of a case like this, California’s consumer protection laws permit courts to issue
14 injunctions that serve different purposes and remedy different harms than retrospective monetary
15 damages.

16 **ii. Standing for Injunctive Relief**

17 I also disagree with WellPet that Zeiger lacks standing to pursue an injunction. In
18 *Davidson v. Kimberly-Clark Corporation*, the Ninth Circuit settled a divide among the district
19 courts of this Circuit “in favor of plaintiffs seeking injunctive relief.” 889 F.3d 956, 969 (9th Cir.
20 2018). It held that “a previously deceived consumer may have standing to seek an injunction
21 against false advertising or labeling, even though the consumer now knows or suspects that the
22 advertising was false at the time of the original purchase.” *Id.*

23 The court discussed two situations that would be sufficient to confer standing. “In some
24 cases, the threat of future harm may be the consumer’s plausible allegations that she will be unable
25 to rely on the product’s advertising or labeling in the future, and so will not purchase the product
26 although she would like to.” *Id.* at 969–70. “In other cases, the threat of future harm may be the
27 consumer’s plausible allegations that she might purchase the product in the future, despite the fact
28 it was once marred by false advertising or labeling, as she may reasonably, but incorrectly, assume

1 the product was improved.” *Id.* at 970.

2 *Davidson* is satisfied here. In response to questioning from WellPet’s counsel, Zeiger
3 testified that he would be “open to” purchasing the Wellness Products again if his issues with it
4 were remedied. *See* Dkt. No. 162-16 at 15:2–13. That statement is more than a convenient
5 litigating position: Zeiger purchased the WellPet products regularly for years prior to learning
6 about the presence of the substances, demonstrating his credible interest in them. *Cf. Lilly v.*
7 *Jamba Juice Co.*, No. 13-CV-02998-JST, 2015 WL 1248027, at *4 (N.D. Cal. Mar. 18, 2015)
8 (“[B]ecause this consumer has already voted with her wallet, we know that she is the most likely
9 to be injured in the absence of an injunction, not the least.”). Unlike some products that are
10 bought rarely, Zeiger’s plausible allegation that he is open to purchasing the Wellness Products in
11 the future makes particular sense as dog food is typically purchased on a relatively regular
12 schedule. Moreover, Zeiger cannot know whether WellPet has begun to remove lead or arsenic
13 absent an injunction requiring warnings if it did not and so plausibly argues that he cannot trust its
14 packaging absent an injunction. *See Davidson*, 889 F.3d at 969–70; *see, e.g., Lilly*, 2015 WL
15 1248027, at *5.

16 WellPet replies that “open to” purchasing it is not sufficient. *See* SJ Mot. 24. But “open
17 to” a purchase—that one regularly purchased before, no less—is at least as firm as *Davidson*’s
18 formulation of a representation that someone “might” purchase the product.

19 WellPet also cites cases in which injunctive relief standing was denied, but none are like
20 the facts here. In *Rahman v. Mott’s LLP*, standing was not denied due to issues with the
21 credibility of a desire to purchase the product again, it was based on that court’s specific finding
22 that the consumer would not be misled by the meaning of a single discrete label because she
23 learned its meaning during litigation. No. 13-CV-03482-SI, 2018 WL 4585024, at *3 (N.D. Cal.
24 Sept. 25, 2018). Whether or not that comports with *Davidson* (which had just been decided), it is
25 not like the situation here: among other distinctions, Zeiger alleges pure omissions, so there is no
26 “meaning” that could be learned to remedy WellPet’s alleged failure to disclose. *Lanovaz v.*
27 *Twinings North American, Inc.*, denied standing because the plaintiff testified she would not
28 purchase the products “even if the company removed the allegedly misleading labels” and because

1 her only statement to the contrary was that she would vaguely “consider” buying them. 726 F.
2 App’x 590, 591 (9th Cir. 2018). And in *Sciacca v. Apple, Inc.*, the court found the plaintiff only
3 testified he would “potentially” repair the watch at issue. 362 F. Supp. 3d 787, 803 (N.D. Cal.
4 2019). That is a distinct situation from the facts here and *Davidson*, where a consumer has an
5 established history of regular purchases and has stated he would be open to purchasing again in
6 the future.

7 Nor does it change the analysis that Zeiger has testified that he would not purchase the
8 products if the labels changed but they still contained the substances. *See* Dkt. No. 162 at 15:16–
9 16–21. Counsel’s questions and Zeiger’s testimony are somewhat muddled; it is not clear from
10 the transcript under exactly what conditions he believed he was saying he would not purchase the
11 product. As noted, he stated he was “open to” purchasing it if he could believe the alleged
12 representations and trust that the omitted information was not material. And *Davidson* teaches
13 that “threat of future harm may be the consumer’s plausible allegations that she will be unable to
14 rely on the product’s advertising or labeling in the future, and so will not purchase the product
15 although she would like to.” 889 F.3d at 969–70.

16 **F. Negligent Misrepresentation**

17 Finally, WellPet argues that Zeiger’s negligent misrepresentation claim is barred by the
18 economic loss rule. As a general matter, that rule “requires a purchaser to recover in contract for
19 purely economic loss due to disappointed expectations, unless he can demonstrate harm above and
20 beyond a broken contractual promise.” *Robinson Helicopter Co. v. Dana Corp.*, 34 Cal. 4th 979,
21 988 (2004). In his Opposition, Zeiger does not address this argument. The negligent
22 misrepresentation claim cannot form the basis of a claim premised on purely economic loss.
23 Zeiger has not alleged any property injury or personal injury from the alleged negligent
24 misrepresentations. Nor does a *negligent* misrepresentation claim fall within the category of
25 *intentional* misrepresentation claims that the California Supreme Court has held are not barred by
26 the rule. *See id.* at 991 (singling out intent as defining feature of the exception). WellPet’s motion
27 is granted on this claim.
28

1 **G. Conclusion**

2 The motion for summary judgment is GRANTED IN PART and DENIED IN PART. It is
3 granted (1) to the extent that Zeiger claims that the amount of BPA in the Wellness Products is a
4 safety risk, (2) with regard to damages, and (3) on the negligent misrepresentation claim. It is
5 otherwise denied.

6 **III. MOTION FOR CLASS CERTIFICATION**

7 Zeiger moves for certification on all of his claims. Zeiger proposes that three classes be
8 certified, one for each of the Wellness Products. His proposed definitions are as follows:

9 Wellness Class: All persons in California who, from July 1, 2013, to the present, purchased
10 Wellness Complete Health Adult Dry Whitefish and Sweet Potato dog food for household
or business use, and not for resale.

11 Wellness Grain-Free Class: All persons in California who, from July 1, 2013, to the
12 present, purchased Wellness Complete Health Adult Grain Free Whitefish and Menhaden
Fish Meal dog food for household or business use, and not for resale.

13 Core Class: All persons in California who, from July 1, 2013, to the present, purchased
14 Wellness CORE Adult Dry Ocean Whitefish, Herring Meal and Salmon Meal dog food for
household or business use, and not for resale.

15 Cert. Mot. 10–11. These classes would exclude “persons or entities who purchased the Wellness
16 Food for business use or resale; government entities; WellPet and its affiliates, subsidiaries,
17 employees, current and former officers, directors, agents, and representatives; and members of this
18 Court and its staff.” *Id.* 11. Zeiger moves primarily for certification under FRCP 23(b)(3) but
19 also proposes an injunctive relief class under FRCP 23(b)(2) and an alternative liability-only class
20 under FRCP 23(c)(4).

21 WellPet’s primary objections to the 23(b)(3) class is that Zeiger has failed to show that
22 common issues predominate because (1) he cannot demonstrate misrepresentation or causation on
23 a class-wide basis and (2) damages cannot be measured on a class-wide basis. WellPet also argues
24 that Zeiger does not satisfy the typicality requirement, lacks standing to pursue some claims, and
25 has not shown that his alternative injunctive relief or liability classes should be certified.

26 **A. Standing**

27 In a class action, standing is satisfied if at least one named plaintiff meets the
28

1 requirements.” *Bates v. United Parcel Serv., Inc.*, 511 F.3d 974, 985 (9th Cir. 2007). “[T]he core
2 component of standing is an essential and unchanging part of the case-or-controversy requirement
3 of Article III.” *Lujan v. Defs. of Wildlife*, 504 U.S. 555, 560 (1992). The plaintiff bears the
4 burden of pleading and showing standing. To do so, he must demonstrate three elements: (1) an
5 “injury in fact,” (2) a “causal connection between the injury and the conduct complained of,” and
6 (3) that it is “likely . . . that the injury will be redressed by a favorable decision.” *Id.* (internal
7 quotation marks and citations omitted). An injury in fact must be “concrete and particularized”
8 and “actual or imminent,” as opposed to “conjectural or hypothetical.” *Id.* To show a causal
9 connection, the injury must only be “fairly traceable” to the challenged conduct. *Id.*

10 WellPet challenges Zeiger’s standing to bring claims on behalf of the proposed class to the
11 extent he alleges that the “natural” representation was false or misleading. WellPet’s Opposition
12 to Cert. Mot. (“Cert. Oppo.”) [Dkt. No. 162] 27. Its argument is identical to the argument
13 discussed above in its motion for summary judgment. *See* Cert. Oppo. 27. For the reasons
14 explained above, Zeiger plausibly relied on the “natural” representation and therefore was
15 cognizably injured as a result of that alleged misrepresentation.

16 **B. Rule 23(a)**

17 **i. Numerosity**

18 FRCP 23(a) requires that “the class is so numerous that joinder of all members is
19 impracticable.” Fed. R. Civ. P. (a)(1). “[C]ourts canvassing the precedent have concluded that the
20 numerosity requirement is usually satisfied where the class comprises 40 or more members, and
21 generally not satisfied when the class comprises 21 or fewer members.” *Twegbe v. Pharmaca*
22 *Integrative Pharmacy, Inc.*, No. CV 12-5080 CRB, 2013 WL 3802807, at *2 (N.D. Cal. July 17,
23 2013).

24 Zeiger has met the numerosity requirement and WellPet has no argument to the contrary.
25 Zeiger’s data shows that WellPet’s total sales in California from the Wellness Products were
26 approximately \$13.7 million. Dkt. No. 151-12 at 15. Accordingly, based on the prices of the units
27 at issue, it is certain that numerous people—far more than 40—would be included in the class.
28

1 **ii. Commonality**

2 FRCP 23(a) requires that “there are questions of law or fact common to the class.” Fed.
3 R. Civ. P. (a)(2). In reality, “commonality only requires a single significant question of law or
4 fact.” *Mazza v. Am. Honda Motor Co., Inc.*, 666 F.3d 581, 589 (9th Cir. 2012).

5 Zeiger meets the commonality requirement, which WellPet does not contest. At least some
6 of the questions at issue here are common to the class, including whether reasonable consumers
7 would be misled by the actionable Wellness Statements and omissions; the level and danger of
8 arsenic and lead in the Wellness Products; and whether WellPet actively concealed its purported
9 knowledge of the inclusion of arsenic, lead, and BPA. *See also* Cert. Mot. 12–13 (listing other
10 potentially common questions). *Cf. Jones v. ConAgra Foods, Inc.*, No. C 12-01633 CRB, 2014
11 WL 2702726, at *5–*6 (N.D. Cal. June 13, 2014) (finding commonality on misleading labelling
12 claims that something was “100% natural” and similar statements).

13 **iii. Typicality and Adequacy**

14 The Rule also requires that “the claims or defenses of the representative parties are typical
15 of the claims or defenses of the class” and “the representative parties will fairly and adequately
16 protect the interests of the class.” Fed. R. Civ. P. 23(a)(3)–(4). The “test of typicality is whether
17 other members have the same or similar injury, whether the action is based on conduct which is
18 not unique to the named plaintiffs, and whether other class members have been injured by the
19 same course of conduct.” *Hanon v. Dataproducts Corp.*, 976 F.2d 497, 508 (9th Cir. 1992). A
20 plaintiff’s claims are considered typical if they are “reasonably co-extensive with those of absent
21 class members; they need not be substantially identical.” *Castillo v. Bank of Am., NA*, 980 F.3d
22 723, 730 (9th Cir. 2020). A plaintiff may not be typical if she is “subject to unique defenses
23 which threaten to become the focus of the litigation.” *Hanon*, 976 F.2d at 508.

24 WellPet’s only 23(a) challenge is to typicality. It argues that Zeiger’s interests would not
25 be aligned with the class and he is subject to unique defenses: (1) Zeiger did not rely on the
26 Wellness Statements or omissions; (2) he made purported admissions about the ubiquity of
27 arsenic, lead, and BPA; (3) he mistrusts the label “natural”; (4) he lacks memory about what
28 products he bought and when; (5) he concedes that pet food manufacturers and he could rely on

1 regulators’ arsenic, lead, and BPA levels; and (6) he bought dog food for his pet sitting business
2 during the class period. *See* Cert. Oppo. 24–27.

3 Many of those arguments depend on or repeat Well Pet’s contentions at summary
4 judgment. I have already rejected WellPet’s arguments about (1) reliance, (2) ubiquity, and (3) the
5 “natural” label.

6 It is not clear that Zeiger’s memory is so imprecise that a sufficiently realistic amount of
7 damages cannot be estimated. Proof of every last purchase of a product like this is not required.
8 Instead, Zeiger can present evidence that he purchased the products with relative regularity over a
9 certain period to the satisfaction of a jury. *See Comcast*, 569 U.S. at 35 (citing *Story Parchment*
10 *Co. v. Paterson Parchment Paper Co.*, 282 U.S. 555, 563 (1931)); *Story Parchment*, 282 U.S. at
11 563 (“Where the tort itself is of such a nature as to preclude the ascertainment of the amount of
12 damages with certainty, it would be a perversion of fundamental principles of justice to deny all
13 relief to the injured person, and thereby relieve the wrongdoer from making any amend for his
14 acts. In such case, while the damages may not be determined by mere speculation or guess, it will
15 be enough if the evidence show the extent of the damages as a matter of just and reasonable
16 inference, although the result be only approximate.”). That he bought some food for his pet sitting
17 business does not matter; he cannot recover for it as the suit is currently structured.

18 WellPet also argues that Zeiger is not an adequate representative because he agreed that the
19 FDA can be trusted to set pet food dangerousness levels. As explained before, the FDA has not
20 set such levels as a matter of regulation. And the question is not whether the FDA’s draft
21 guidance is correct, it is whether reasonable consumers would be misled.

22 Zeiger’s claims are sufficiently typical of the class and he is in adequate representative.

23 **C. Rule 23(b)(3)**

24 A Federal Rule of Civil Procedure 23(b)(3) class can be certified if “the court finds that the
25 questions of law or fact common to class members predominate over any questions affecting only
26 individual members, and that a class action is superior to other available methods for fairly and
27 efficiently adjudicating the controversy.”

28

1 **i. Predominance and Superiority**

2 The Rule provides that the following factors are “pertinent” to the predominance and
3 superiority inquiry: “(A) the class members’ interests in individually controlling the prosecution or
4 defense of separate actions; (B) the extent and nature of any litigation concerning the controversy
5 already begun by or against class members; (C) the desirability or undesirability of concentrating
6 the litigation of the claims in the particular forum; and (D) the likely difficulties in managing a
7 class action.” Fed. R. Civ. P. 23(b)(3). “The Rule 23(b)(3) predominance inquiry tests whether
8 proposed classes are sufficiently cohesive to warrant adjudication by representation.” *Amchem*
9 *Prod., Inc. v. Windsor*, 521 U.S. 591, 623 (1997).

10 Here, the common questions predominate over any individual ones. The central common
11 questions include (1) whether the statements and omissions would be material to a reasonable
12 consumer; (2) whether arsenic, lead, and BPA are safe and/or nutritious; and (3) whether WellPet
13 could have removed those substances from its products. WellPet’s defenses—many of which it
14 presented at summary judgment on Zeiger’s individual claims—are likely to be the other side of
15 this coin: It is likely to argue that the amount of arsenic, lead, and BPA in its products is safe; that
16 its Wellness Statements are not misleading; that any omission was not misleading; that it had no
17 duty to disclose the presence of arsenic, lead, and BPA; and that it could not remove all traces
18 from its products. The individual questions have largely to do with which and what amount of
19 product each class member purchased, a typical issue to handle in an individualized way in a class
20 action. *See Leyva v. Medline Indus. Inc.*, 716 F.3d 510, 514 (9th Cir. 2013).

21 WellPet’s merits argument is that common issues do not predominate because “deception
22 and causation” cannot be measured on a class-wide basis.

23 1. Uniform Meaning and Materiality

24 WellPet first argues that,

25 Zeiger has not shown that the proposed class uniformly understands the challenged
26 statements as (in his view) representing that the Wellness products are completely free of
27 trace amounts of elements that exist everywhere in the environment and are found in nearly
28 all pet food as well as in human food. As a result, Zeiger has not demonstrated that these
alleged “misrepresentations” are material as to all class members.

1 Cert. Oppo. 14. Relatedly, it asserts that the statements would not have the same *meaning* to all
2 class members. *Id.* at 14–15.

3 This objection is foreclosed both by the nature of California consumer protection law and
4 by my summary judgment determinations. The inquiry under California law is based on what a
5 reasonable consumer would believe, not each idiosyncratic individual. *See, e.g., Ebner*, 828 F.3d
6 at 965; *Krommenhock v. Post Foods, LLC*, 334 F.R.D. 552, 563–64 (N.D. Cal. 2020). As I held at
7 summary judgement, given the admissible evidence of the dangerousness of accumulation of lead
8 and arsenic, a reasonable consumer could believe the omission of that information was material.
9 That issue is to be resolved at trial. The statements need not have had identical subjective
10 meanings to each consumer because California applies an objective reasonable consumer test.

11 2. Variance in Packaging

12 WellPet contends that the packaging varied too greatly during the class period for class
13 treatment. *See* Cert. Oppo. 11–14. Of course, this would not be a barrier to Zeiger’s pure
14 omission theory, as he correctly argues in reply. Even if the packaging varied considerably, it
15 would be irrelevant if WellPet had an independent duty to disclose the presence of arsenic and
16 lead based on safety concerns.

17 The Wellness Statements require more analysis, because (unlike the omissions) they varied
18 between products and over time. To help remedy the problems that may be caused by this
19 variation, Zeiger moves to certify three classes, one based on each of the products. That approach
20 makes sense because one of WellPet’s objections is that the configuration of Wellness Statements
21 varied by product. But WellPet argues that even separating out the class by product is insufficient
22 because the Wellness Statements on each product varied within the class period.

23 Courts applying California consumer protection law at class certification have often
24 confronted these types of arguments. Depending on the nature and extent of the variation, they
25 have come out on both sides. The law does not demand that the statements be identical for every
26 moment of the class period; courts have typically held that the predominance requirement is met
27 when there were relatively insubstantial variations. *See, e.g., Krommenhock*, 334 F.R.D. at 563–
28 64 (“The relevant analysis under California law does not consider whether each class member saw

1 and relied on each of the Challenged Statements and in what combination, but instead whether the
2 Challenged Statements were used consistently through the Class Period, supporting an inference
3 of classwide exposure, and whether the Challenged Statements would be material to a reasonable
4 consumer.”); *Combe v. Intermark Commc’ns, Inc.*, No. CV0909127SJOPJWX, 2010 WL
5 11597517, at *8 (C.D. Cal. Nov. 18, 2010) (discussing “minor variations” that do not change the
6 “center of gravity”).

7 But at some point, the alleged misrepresentations might vary to such a degree to make
8 class-wide determinations impracticable. *See, e.g., Reitman v. Champion Petfoods USA, Inc.*, No.
9 CV181736DOCJPRX, 2019 WL 7169792, at *9 (C.D. Cal. Oct. 30, 2019), *aff’d*, 830 F. App’x
10 880 (9th Cir. 2020) (“Defendants point to numerous issues requiring individualized attention that
11 would predominate over any common questions. For example, Defendants show the Court that
12 the phrases at issue require context that differs from bag to bag.”); *see also Krommenhock*, 334
13 F.R.D. at 566 n.10 (distinguishing *Reitman* on numerous bases, including the creation of
14 subclasses). A presumption of reliance does not arise when class members “were exposed to *quite*
15 disparate information from various representatives of the defendant.” *Mazza v. Am. Honda Motor*
16 *Co.*, 666 F.3d 581, 596 (9th Cir. 2012) (emphasis added). In *Mazza*, for instance, the claims were
17 predicated on an advertising campaign that was a “limited campaign” of brochures and
18 commercials, which the court held insufficient to imply class-wide reliance. *Id.*

19 WellPet makes three types of arguments on this front. The first is that the placement, size,
20 and appearance of the Wellness Statements changes, the second is that the context given for the
21 Wellness Statements changes, and the third is that which Wellness Statements are on each product
22 change. Because the classes would be by product, I describe the changes that occurred for each
23 product during the class period.

24
25
26
27
28


1 CORE Ocean Product. “Uncompromising nutrition” and “with nothing in excess and
2 everything in balance” were on the packaging from “mid-to-late” 2013 until spring 2016. Cert.
3 Oppo. 12–13. The size of “uncompromising nutrition” also changed and it moved from the back
4 of the packing around spring 2016. *Id.* “Unrivaled quality standards” has been on the packaging
5 since spring 2016. *Id.* “Complete health” does not appear on the product. *Id.* “Natural” has
6 always appeared. The following versions of the packaging have been on the market during the
7 class period (left to right from earliest to latest):



21 See Dkt. Nos. 162-4, 162-5, 162-6, 162-7.

22 Sweet Potato Product. “Uncompromising nutrition” has been on the product for the entire
23 period; in spring 2016, it was moved from the back to the front and its font size and surrounding
24 material changed. Cert. Oppo. 13. “Unrivaled quality standards” has been on the packaging since
25 spring 2016. *Id.* “With nothing in excess and everything in balance” did not appear on the
26 packaging. “Natural” has always appeared. “Complete health” has always been prominently
27 displayed. The following versions of the packaging have been on the market during the class
28 period (left to right from earliest to latest):

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28



See Dkt. Nos. 162-8, 162-9 (reformatted for consistency), 162-10.

Menhaden Product. WellPet does not argue there has been any change in the Menhaden product's packaging, which looked like this during the class period:



See Dkt. No. 162-11.

As an initial matter, even if WellPet's argument were accepted, it would not stand in the way of certifying classes in several specific ways. WellPet identifies no changes in the Menhaden Product, so its arguments on this point are not a barrier to certification of that class. There is also

1 no dispute that some Wellness Statements have been virtually unchanged on the other two
2 products (such as “complete health” on the Sweet Potato Product), so the classes could be certified
3 as to those statements alone. And, as noted above, classes could be certified on the pure omissions
4 for all three products. I therefore turn to whether the changes in the other Wellness Statements
5 defeat predominance for the CORE Ocean and Sweet Potato Products

6 The changes that WellPet identifies between the Wellness Statements do not mean that
7 individual issues predominate. WellPet’s attempts to present the bags as being in a constantly-
8 changing state of flux do not persuade. As the summaries and images above made clear, two of
9 the three products went through a few relatively minor changes over the course of many years.
10 The most significant of the changes occurred around spring 2016.

11 Setting this aside, WellPet’s predominance argument is fundamentally misplaced. The
12 changes that occurred here are (1) by product and (2) occurred relatively uniformly over time.
13 Zeiger has moved to certify classes by product. Accordingly, whether common questions
14 predominate depends on whether they predominate for each product. Because these variations
15 happened over time, they happened at the same time for the entire class, give or take the time for
16 each product to be phased out. Put another way, the alleged misrepresentations would be the same
17 *for the class* at any given time.

18 There might be some level of individual uncertainty that results from the transition time
19 between each packaging version. There will inevitably be some amount of time in which the old
20 packaging is on store shelves after the new version has been rolled out. But this issue can be dealt
21 with as one of individualized *damages*. A jury can still determine whether each version of the
22 packaging would mislead a reasonable consumer and, assuming an admissible damages model,
23 can calculate its value. The question of which bag a consumer bought would be, as always,
24 individual. *See Yokoyama v. Midland Nat. Life Ins. Co.*, 594 F.3d 1087, 1094 (9th Cir. 2010).
25 Any uncertainty about which of two possible versions on the market an individual purchased does
26 not mean that that individual issue predominates.

27 This makes this case unlike *Reitman*, the most factually similar case WellPet has pointed to
28 that denied class certification. There, the Ninth Circuit held that the district court did not abuse its

1 discretion in denying class certification based on the wide variation in the packaging of products
2 that would result in “individualized inquiries requiring bag-to-bag determinations.” *Reitman v.*
3 *Champion Petfoods USA, Inc.*, 830 F. App’x 880, 881 (9th Cir. 2020). The district court
4 explained that at issue there were 23 different dog food formulas. *Reitman v. Champion Petfoods*
5 *USA, Inc.*, No. CV181736DOCJPRX, 2019 WL 7169792, at *1 n.1 (C.D. Cal. Oct. 30, 2019).
6 The phrases that were challenged varied across all of these different bags types. *Id.*, at *9. For
7 instance, the phrase “regional” was used to describe ingredients sometimes (which was alleged to
8 be misleading) but other times, “local” was used along with specific source identifiers for
9 ingredients. *Id.* Another example was that the ingredients identified as “fresh” varied from bag to
10 bag, so consumers would not be looking at the same representations. *Id.* Consequently, the court
11 found that there was a threat that the misrepresentations were truly individualized because the
12 class members were presented with many varying bags. *Mazza* is even farther from these facts.
13 That case concerned a limited advertising campaign that many consumers may have seen different
14 parts of or not seen at all. Here, the statements are on packaging.

15 There is one class for each formula here. While the packaging for each looks different, the
16 changes *within* each formula type are relatively minor, occurred over time in an essentially
17 uniform way, and can be addressed class-wide. Accordingly, common issues predominate.⁸

18 Zeiger has also shown that a class action is a superior mode of adjudication. Based on the
19 amount at stake for any individual, it would be impracticable for them to carry out a full consumer
20 protection case, especially given the expertise required in this one. A class action, on the other
21 hand, would permit a jury to determine essentially all of the important questions in the suit on a
22 class-wide basis. WellPet makes no specific arguments to the contrary on this point (though some
23 of its predominance arguments implicate superiority; to that extent, they are rejected).

24 **ii. Damages**

25 “In this circuit . . . damage calculations alone cannot defeat certification.” *Yokoyama*, 594

26 _____
27 ⁸ Moreover, although not necessary to the outcome, the changes in each particular Wellness
28 Statement are not the primary economic focus of this case. Despite the flaws in Zeiger’s damages
model, it at least shows that the value attached to the pure omissions dwarf the value of any
Wellness Statement or combination of them.

1 F.3d at 1094. This is so because “the amount of damages is invariably an individual question and
2 does not defeat class action treatment.” *Id.* (internal quotation marks and alteration omitted).
3 “Thus, the presence of individualized damages cannot, by itself, defeat class certification under
4 Rule 23(b)(3).” *Leyva v. Medline Indus. Inc.*, 716 F.3d 510, 514 (9th Cir. 2013).

5 However, “plaintiffs must be able to show that their damages stemmed from the
6 defendant’s actions that created the legal liability.” *Id.*; *see generally Comcast Corp. v. Behrend*,
7 569 U.S. 27 (2013). Accordingly, a “damages model must measure only those damages
8 attributable to the plaintiff’s theory of liability. If the plaintiff does not offer a plausible damages
9 model that matches her theory of liability, the problem is not just that the Court will have to look
10 into individual situations to determine the appropriate measure of damages; it is that Plaintiffs
11 have not even told the Court what data it should look for.” *Hadley*, 324 F. Supp. 3d at 1103
12 (internal quotation marks and citations omitted).

13 For the reasons explained above, Zeiger’s model for assessing damages is not admissible
14 under *Daubert*. The issue is not that damages will be individualized, it is that Zeiger has not put
15 forward a damages model that can reliably show the price premium for the alleged
16 misrepresentations. It appears possible, however, for Zeiger to put forward a price premium
17 model that reliably values a class member’s harm and this single ground for denying certification
18 is narrow. Accordingly, leave to bring a renewed motion to certify the class with such a model is
19 granted. *See Zinser v. Accufix Research Inst., Inc.*, 253 F.3d 1180 (9th Cir.), *opinion amended on*
20 *denial of reh’g*, 273 F.3d 1266 (9th Cir. 2001) (reviewing a renewed motion to certify after a
21 district court denied the first motion on specific grounds). As it stands, however, a 12(b)(3) class
22 cannot be certified because there is not a sufficient showing that damages can be accurately
23 calculated. The motion to certify the class is therefore DENIED WITHOUT PREJUDICE.

24 **D. Rule 23(b)(2)**

25 Zeiger also moves to certify a class under Federal Rule of Civil Procedure 23(b)(2). Under
26 that rule, a class may be certified if WellPet “has acted or refused to act on grounds that apply
27 generally to the class, so that final injunctive relief or corresponding declaratory relief is
28 appropriate respecting the class as a whole.” Fed. R. Civ. P. 23(b)(2). A 23(b)(2) action does not

1 offer damages; instead, “certification under Rule 23(b)(2) is appropriate only where the primary
2 relief sought is declaratory or injunctive.” *Zinser*, 253 F.3d at 1195.

3 Zeiger has shown that such a 23(b)(2) class should be certified. For the reasons explained
4 above, and incorporated here, there are many common questions at stake that predominate over
5 individual ones. WellPet’s actions are alleged to be equally applicable to the entire class.
6 Injunctions against WellPet, if successful, would prohibit the alleged misrepresentations as to all
7 class members.

8 WellPet has several responses, but most are restatements of arguments that have already
9 been addressed. *See* Cert. Oppo. 27–28. Its novel argument is that the *primary* relief here is not
10 injunctive, so a Rule 23(b)(2) class is inappropriate. But a major goal of California’s consumer
11 protection law is prevention of future consumer protection violations through injunctive relief.
12 *See, e.g., In re Tobacco II Cases*, 46 Cal. 4th at 319 (“[T]he primary form of relief available under
13 the UCL to protect consumers from unfair business practices is an injunction.”). There is no
14 reason to think that injunctive relief against future harm is less important than monetary relief for
15 past harm. To hold otherwise would bar an injunctive relief class merely because damages are
16 also available. Additionally, damages are not the main focus of the 23(b)(2) class in any case, so
17 the primary focus of that class would be injunctive relief. Indeed, at this point, no damages class
18 will proceed. The motion to certify Rule 12(b)(2) classes with the class definitions above is
19 GRANTED.

20 **E. Rule 23(c)(4)**

21 Zeiger alternatively moves to certify a liability-only class under Rule 23(c)(4). That rule
22 provides that, “[w]hen appropriate, an action may be brought or maintained as a class action with
23 respect to particular issues.” Fed. R. Civ. P. 23(c)(4). It is intended to allow “isolate[ion of] the
24 common issues . . . and proceed with class treatment of these particular issues.” *Valentino v.*
25 *Carter-Wallace, Inc.*, 97 F.3d 1227, 1234 (9th Cir. 1996). Zeiger’s proposal is to jettison damages
26 and decide the remaining common issues on liability.

27 At the hearing on these motions, I indicated that I would grant leave to recertify the class if
28 the damages issue were all that stood in the way. Zeiger’s counsel indicated that they could put

1 forward an admissible damages model after seeing my ruling. Because Rule 23(c)(4) is the
2 fallback, certification is DENIED WITHOUT PREJUDICE on the understanding that Zeiger will
3 move to certify a class with an appropriate damages model. At that time, Zeiger may also move
4 for a 23(c)(4) class as an alternative if he wishes. If—after reviewing this ruling and consulting
5 with experts—Zeiger concludes that no admissible damages model can be put forward, he may
6 also elect to move again for a Rule 23(c)(4) class if he wishes. If he does so, he should illustrate
7 that there is sufficient added utility to doing so in light of the 23(b)(2) certification.

8 **IV. MOTIONS TO SEAL**

9 Courts “start with a strong presumption in favor of access to court records.” *Foltz v. State*
10 *Farm Mut. Auto. Ins. Co.*, 331 F.3d 1122, 1135 (9th Cir. 2003). The public possesses a right to
11 inspect public records, including judicial records. *Ctr. for Auto Safety v. Chrysler Grp., LLC*, 809
12 F.3d 1092, 1096 (9th Cir. 2016). Accordingly, when a party seeks to seal judicial records
13 connected to motions—such as the one at issue here—that are “more than tangentially related to
14 the underlying cause of action,” it “must demonstrate that there are ‘compelling reasons’ to do so.”
15 *Id.* at 1096–99. “When ruling on a motion to seal court records, the district court must balance the
16 competing interests of the public and the party seeking to seal judicial records.” *In re Midland*
17 *Nat. Life Ins. Co. Annuity Sales Practices Litig.*, 686 F.3d 1115, 1119 (9th Cir. 2012). This
18 district’s local rules require that requests to seal be “narrowly tailored to seek sealing only of
19 sealable material.” CIV. L. R. 79-5(b).

20 WellPet seeks to redact and seal information and exhibits. *See* Dkt. Nos. 160, 188, 192.
21 The motions are GRANTED.⁹ The information it seeks to seal is narrowly tailored and falls into
22 two sealable categories. First, WellPet seeks to redact the suggested and minimum prices for its
23 products (the prices charged are public) as well as its strategy for determining those prices. *See*
24 Dkt. Nos. 160-1, 160-3, 192. These redactions are narrow and the information could reasonably
25 place WellPet at a competitive disadvantage if disclosed. *See Nixon v. Warner Commc’ns, Inc.*,
26 435 U.S. 589, 598 (1978). To the extent that prices matter to the labelling debate discussed, that

27 _____
28 ⁹ Zeiger’s motion to seal at Dkt. No. 173 is DENIED because WellPet has indicated it no longer
wishes to seal the information at issue. *See* Dkt. No. 176. Dkt. No. 173 shall be UNSEALED.

1 information is disclosed in the parties' briefs; accordingly, this information does not require
2 sealing anything in this Order. Should this information become important at trial, including for
3 purposes of calculating damages, it will be unsealed. Second, WellPet moves to redact individual
4 consumers' identifying information, which is plainly sealable and narrowly tailed. *See Opperman*
5 *v. Path, Inc.*, No. 13-CV-00453-JST, 2017 WL 1036652, at *7 (N.D. Cal. Mar. 17, 2017).


6 **CONCLUSION**

7 The motions to exclude and motion for summary judgment are GRANTED IN PART and
8 DENIED IN PART as described. The motion to certify a 23(b)(3) class is DENIED WITHOUT
9 PREJUDICE. The motion to certify a 23(b)(2) class is GRANTED.

10 The parties may stipulate to a schedule for creation of a new expert report, discovery on
11 that report, a renewed motion to certify, and (perhaps) a *Daubert* motion from WellPet about the
12 proffered damages model. Renewed briefing on class certification should focus exclusively on the
13 damages model because the issues have otherwise been settled; the page limits for both a motion
14 to certify and a *Daubert* motion shall be 15 for motions and oppositions and 8 for replies. If the
15 parties cannot agree to a schedule within 21 days, they should submit a joint letter brief of no more
16 than 5 pages total laying out their proposed timelines and I will set one.

17 **IT IS SO ORDERED.**

18 Dated: February 26, 2021

19
20 
21 William H. Orrick
22 United States District Judge
23
24
25
26
27
28